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1, Summary  
The iron storage protein, ferritin, plays a key role in 
iron metabolism. Its ability to sequester the element gives 
ferritin the dual functions of iron detoxification and iron 
reserve. The importance of these functions is emphasised 
by ferritin's ubiquitous distribution among living species. 
Ferritin's three-dimensional structure is highly conserved. 
All ferritins have 24 protein subunits arranged in 432 
symmetry to give a hollow shell with an 80 A diameter 
cavity capable of storing up to 4500 Fe(III) atoms as an 
inorganic complex. Subunits are folded as 4-helix bundles 
each having a fifth short helix at roughly 60 ° to the bundle 
axis. Structural features of ferritins from humans, horse, 
bullfrog and bacteria re described: all have essentially the 
same architecture in spite of large variations in primary 
structure (amino acid sequence identities can be as low as 
14%) and the presence in some bacterial ferritins of haem 
groups. Ferritin molecules isolated from vertebrates are 
composed of two types of subunit (H and L), whereas 
those from plants and bacteria contain only H-type chains, 
where 'H-type'  is associated with the presence of centres 
catalysing the oxidation of  two Fe(II) atoms. The similarity 
between the dinuclear iron centres of ferritin H-chains and 
those of ribonucleotide reductase and other proteins sug- 
gests a possible wider evolutionary linkage, A great deal of 
research effort is now concentrated on two aspects of 
ferritin: its functional mechanisms and its regulation, These 
form the major part of the review. Steps in iron storage 
within ferritin molecules consist of Fe(II) oxidation, Fe(l l I)  
migration and the nucleation and growth of the iron core 
mineral. H-chains are important for Fe(II) oxidation and 
L-chains assist in core formation, Iron mobilisation, rele- 
vant to ferritin's role as iron reserve, is also discussed. 
Translational regulation of mammalian ferritin synthesis in 
response to iron and the apparent links between iron and 
citrate metabolism through a single molecule with dual 
function are described. The molecule, when binding a 
[4Fe-4S] cluster, is a functioning (cytoplasmic) aconitase. 
When cellular iron is low, loss of  the [4Fe-4S] cluster 
allows the molecule to bind to the 5'-untranslated region 
(5'-UTR) of the ferritin m-RNA and thus to repress transla- 
tion. In this form it is known as the iron regulatory protein 
(IRP) and the stem-loop RNA structure to which it binds is 
the iron regulatory element (IRE). IREs are found in the 
3'-UTR of the transferrin receptor and in the 5'-UTR of 
erythroid aminolaevulinic acid synthase, enabling tight 
co-ordination between cellular iron uptake and the synthe- 
sis of ferritin and haem. Degradation of ferritin could 
potentially lead to an increase in toxicity due to uncon- 
trolled release of iron. Degradation within membrane-en- 
capsulated 'secondary lysosomes' may avoid this problem 
and this seems to be the origin of another form of storage 
iron known as haemosiderin. However, in certain patholog- 
ical states, massive deposits of 'haemosiderin' are found 
which do not arise directly from ferritin breakdown. Un- 
derstanding the numerous inter-relationships between the 
various intracellular i on complexes presents a major chal- 
lenge. 
2. Introduction 
2.1. Iron metabolism and the importance of  iron storage 
The importance of iron in biology reflects both its 
chemical versatility and its abundance. It is the second 
most abundant metal in the earth's crust (after aluminium). 
One of the properties of iron (not shared by aluminium), 
which has been widely exploited, is its ability to change 
valence. This ability can be subtly modified by a variety of 
organic ligands to provide electron transport proteins with 
a wide range of redox potentials. Iron is also found at the 
active centres of many enzymes and of  oxygen carrier 
proteins. 
P.M. Harrison, P. Arosio / Biochimica et Biophysica Acta 1275 (1996) 161-203 163 
However, there are problems in the physiological man- 
agement of iron which have arisen from the increase in 
atmospheric oxygen since early times. One such problem 
is that despite its overall abundance, usable iron is in short 
supply. This is because, at physiological pH under oxidis- 
ing conditions, iron is extremely insoluble. Several strate- 
gies must therefore be adopted for its acquisition. Bacteria 
and fungi mainly acquire iron by production of 'sidero- 
phores' - small organic molecules with a very high affin- 
ity for Fe(III), which act as scavengers [1-3]. The synthe- 
sis of these compounds, the uptake of the Fe(III) com- 
plexes, and the release of this iron inside the cell require 
the action of a complex array of proteins [4-8]. Plants 
adopt several strategies for iron assimilation from soil 
(reviewed in Ref. [9]). They may exploit siderophores 
produced by symbiotic micro-organisms, ynthesize and 
release their own chelating molecules, release protons or 
organic acids leading to localised lowering of soil pH, or 
synthesise reductants, which convert Fe(III) to the more 
soluble Fe(II). Roots also contain specific plasma mem- 
brane translocating systems. Higher animals, e.g., man, 
acquire iron from foodstuffs. Here bioavailability may 
again be limited. Plants tend to be a poor source of iron, 
because of the presence of phosphates, phytates and 
polyphenols, all of which inhibit absorption by formation 
of insoluble complexes. Meat is a better source of iron, 
because haem is readily absorbed. 
The functional importance of iron, coupled with its 
generally poor bioavailability, make it essential for living 
organisms to husband this element. Virtually all life forms 
require iron except for some strains of lactobacillus, where 
the role of iron may be assumed by another metal such as 
Co or Mn. The iron-storage molecule, ferritin, is also 
ubiquitous. A second form of storage iron, haemosiderin, 
is found in both plants and animals. It is generally associ- 
ated with high cellular iron levels. 
Most of the iron present in living organisms is tightly 
complexed in proteins, although it may also be present in a 
soluble 'pool' of low molecular weight complexes such as 
ferric citrate and Fe(III) ATP [10]. Free iron concentrations 
are low: not more than about 10 -18 M Fe(III) and about 
10 -8 M Fe(II) [11]. Uncomplexed iron together with 
superoxide (which reduces Fe(III), Eq. (1)) and hydrogen 
peroxide (which is decomposed by the Fenton reaction, 
Eq. (2)) provide a lethal mixture containing reactive hy- 
droxyl radicals. The sum of these two reactions is the 
so-called iron-catalysed Haber-Weiss reaction [12] (Eq. 
(3)). Fe(III) produced as in Eq. (2) can also be reduced by 
ascorbate l ading to further adical production. 
Fe3+ + O2 - --+ Fe2+ + O2 ( I )  
Fe e+ + H202 --+ Fe 3+ + OH- + OH • (2) 
02-+ H202 "+ 02 + OH-+ OH. (3) 
The hydroxyl radical is extremely reactive causing lipid 
peroxidation, DNA strand breaks and degradation of other 
biomolecules [13]. In vertebrates defence against he toxic 
effect of Fe and oxygen mixtures is provided by two 
specialised iron-binding proteins: the extracellular t ansfer- 
fins and the intracellular ferritins. Both retain iron in a safe 
Fe(III) form, which, unless mobilised, will not catalyse the 
production of free radicals. Iron is stored mainly intra- 
cellularly, where its potentially damaging effects are great- 
est. Hence the design and regulation of the major iron 
storage protein are of great importance. Ferritin's protec- 
tive ability is based on its capacity to transform the highly 
toxic Fe(II) into the less toxic Fe(III) and to sequester it in 
its cavity. The major role of ferritin in vertebrates is in iron 
storage, whereas in prokaryotes it may be more important 
as an iron detoxifier and in efficient iron management 
functions associated with its ability to oxidise and incorpo- 
rate iron. 
2.2. Iron metabolism in humans: an outline 
Human iron metabolism and absorption has been the 
subject of a recent review [14]. Normal human males 
contain 3-5 g of iron (often less in females) and, of this, 
two-thirds is in circulating red cells as haemoglobin and 
15-25% in storage as ferritin and haemosiderin [15,16]. 
The remaining iron is in muscle myoglobin (about 8%) 
and in cytochromes and iron-containing enzymes. Plasma 
transferrin accounts for only 3 mg Fe, but the daily 
exchange of iron through plasma transferrin is ten times 
this amount. Transferrin therefore plays a central role in 
iron distribution. It accepts iron from reticuloendothelial 
cells (22 mg daily released by destruction of effete red 
cells), from parenchymal tissues (7 mg/day) and from the 
mucosal cells of the intestine (1 mg/day) and delivers it to 
the erythroid marrow (22 mg daily) and other tissues for 
synthesis of 'functional' iron proteins and for storage. Iron 
delivery by transferrin to erythroid and many non-erythroid 
cells involves interaction of transferrin with specific recep- 
tors followed by endocytosis and recycling of apotransfer- 
rin and the receptor [ 17-19]. These receptors are present in 
low amounts on phagocytic ells which receive their iron 
from degraded red cell haemoglobin. In the case of hepato- 
cytes it has been proposed that iron is released by reduc- 
tion at the plasma membrane [20] rather than by receptor- 
mediated endocytosis, but there is no evidence for a difer- 
ric reductase in rat liver plasma membranes [21]. Under 
pathological conditions (e.g., iron overload or serum trans- 
ferrin deficiency) the amount of iron not bound to transfer- 
fin may become important. This is distributed to organs in 
an inappropriate manner leading to iron overload in 
parenchymal organs such as liver and pancreas [22]. Fe(III) 
bound to citrate, nitriloacetate or other complexes i  effi- 
ciently taken up by cultured cells. Ferritin may also carry 
significant amounts of iron between liver Kupffer cells and 
hepatocytes [23]. How iron is recycled to the blood stream 
is obscure. Serum transferrin appears to have an important 
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role in this recycling, and animals or patients with congeni- 
tal hypotransferrinaemia develop iron overload. Particu- 
larly interesting is the recent observation that subjects with 
a congenital absence of ceruloplasmin also develop severe 
iron overload [24], supporting the hypothesis that the cop- 
per protein is involved in the transfer of iron to transferrin, 
possibly because of its ferroxidase activity. 
The major sites of iron storage are the liver (about 
one-third), spleen and bone marrow. Muscle is also quanti- 
tatively important because of its large mass, although the 
actual concentration of storage iron (40 mg/kg)  is low 
[25]. In the gastrointestinal mucosa, ferritin plays a role in 
the regulation of iron entry into the body by sequestering 
unneeded iron which is lost when the cells are desqua- 
mated [14,26]. However, the level of ferritin in the gut of 
subjects with chronic iron overload is not exceptionally 
high [27]. Only about 1 mg Fe/day is absorbed into the 
body in normal healthy adults, this amount representing 
only about 10% of food iron. Although not all of the latter 
is readily absorbable there are mechanisms regulating in- 
take. These are poorly understood, but intake is responsive 
to total body iron stores such that subjects with low 
storage iron (e.g., in iron deficiency) absorb more. An 
increased rate of erythropoiesis also leads to increased 
absorption. Absorption inappropriate to the amount of 
storage iron does occur. Dietary iron overload is uncom- 
mon, but 'Bantu siderosis', due to repeated consumption 
of beer brewed in iron containers and manifested by 
increased storage iron in liver, spleen and bone marrow, 
has been well characterised [15]. Genetic (idiopathic or 
hereditary) haemochromatosis i  one of the most common 
genetic disorders in western populations, particularly 
among Celtic peoples [28-30]. This disease is associated 
with greatly increased (sometimes 50-fold) deposits of 
storage iron, predominantly as haemosiderin, in the liver 
and other tissues due to abnormally high absorption from 
the gut, although there seems to be little or no ferritin in 
the duodenal absorption cells [31]. Genetic haemochro- 
matosis has an autosomal recessive mode of inheritance 
with a gene locus tightly linked to the HLA-A locus on 
chromosome 6 of the histocompatibility antigen complex 
[28]. In spite of intense research, the biochemical nature of 
the primary defect has not been established. Abnormally 
high iron stores are also found as a secondary effect 
arising from ineffective rythropoiesis (e.g., the defective 
globin synthesis of the thalassaemias) [30]. These 'iron- 
loading anaemias' are associated with increased absorption 
and are also treated by blood transfusion. The excess iron 
cannot be eliminated and must be stored. A characteristic 
feature of humans is that their means of excretion is 
limited. Only about 1 mg/day is lost, mainly through the 
gut and to a less extent through the urine (0.1 mg) and 
skin. A fine internal balance must be maintained between 
iron released from macrophages and iron incorporated into 
developing erythroid cells. 
Elevated body iron leads to increased iron in storage 
(and not to increases in haemoglobin, myoblobin, etc., 
except in the treatment of iron deficiency anaemia). Under 
normal iron loading, ferritin is the major storage form, but, 
in diseases of iron overload, the capacity to synthesize 
ferritin levels off and haemosiderin becomes predominant 
[32]. Ferritin can be seen by electron microscopy as tiny 
dense particles dispersed in the cytosol [33]. Haemosiderin 
may also be visualised by electron microscopy. Together 
with some ferritin, it is found in membrane-bound bodies 
or 'siderosomes' derived from secondary lysosomes, al- 
though clusters of electron-dense material without mem- 
branes, or only partially enclosed by membranes, are also 
observed [33]. Haemosiderin is also revealed by Perl's 
staining of liver sections, whereas the dispersed ferritin 
gives only a faint Prussian blue background. In most forms 
of iron overload, storage iron is increased relatively in 
Kupffer and other phagocytic ells, whereas in primary 
(genetic) haemochromatosis there is a preferential loading 
of liver hepatocytes. Both forms of storage iron are mobil- 
isable. Treatment of genetic overload is usually by phle- 
botomy and of iron-loading anaemias by treatment with 
iron chelating agents. In iron deficiency, storage iron is 
decreased and may be totally absent. 
2.3. Scope of  the reuiew 
This review concentrates on the following aspects of 
iron storage: 
1. how does the molecular architecture of ferritin enable it 
to store iron? To what extent is this architecture con- 
served? 
2. what are the iron storage mechanisms? 
3. what are the roles of the different subunits in vertebrate 
ferritins? 
4. how is ferritin iron made available? 
5. how is ferritin biosynthesis regulated? 
6. what is the relationship between ferritin and 
haemosiderin iron overload? 
7. does the iron-storage molecule, ferritin have other bio- 
logical functions? 
3. Ferritin molecules: their distribution and structures 
3.1. Ferritin protein shells of  animals, plants and bacteria 
3.1.1. Definition, distribution, primary structures, isofer- 
ritins 
The ferritin molecule is a hollow protein shell (outside 
diameter 12-13 nm, inside 7-8 nm, M r about 500000), 
composed of 24 polypeptide chains and capable of storing 
up to 4500 Fe(III) atoms as an inorganic omplex [34,35]. 
It has been isolated from a wide range of sources. 
Among vertebrate f rritins those from man, horse, sheep, 
pig, rabbit, rat, mouse, chicken and tadpole have been 
extensively characterised with complete or partial amino 
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acid sequences (see Refs. [36,37] for review). Two ferritins 
from the snail Lymnaea stagnalis (located in either soma 
or yolk) have been isolated and their cDNA and amino 
acid sequences determined [38]. Two ferritins of different 
primary structures have been found in the parasite Schisto- 
soma mansoni, one more prevalent in females and the 
Table 1 
Amino acid sequences of some ferritins 
HumH 
EcBFR 
AvBFR 
MIBFR 
MaBFR 
BmBFR 
A B 
1 * 77 
MKGDTKVINYLNKLLGNELVAINQYFLHARMFK. .NWGLKR£NDVEYHESIDEMKHADRYIER ILFLEGLPNLQDLGKL .... 
MKGDKIV IQHLNKILGNEL IA INQYFLHARMYE. .DWGLEKLGKHEYHESIDEMKHADKL IKR ILFLEGLPNLQELGKL  .... 
MQGDPDVLRLLNEQLTSELTAINQYFLHSKMQE. .NWGFTELAERTRVESFDEMRHAEAITDRILLLDGLPNYQKIGS ..... 
MQGDPEVLRLLNEQLTTQLTAINQYFLHSKMQD. .NWGFTELAEHTRAESFDEMRHAEAITDRILLLDGLPNYQRLFSL  .... 
MKGEPKVIERLNDALFLELGAVNQYWLHYRLLN. .DWGYTRLAKKEREES IEEMHHADKL INRI IFFEGFPNLQTVSPL  .... 
EcFTN 
HpFTN 
Soy 
Mai l  
Schl 
Sch2 
Lyml 
Lym2 
Sal l  
Sal2 
B fMF  
B fHF  
ChHF 
MoHF 
HuHF 
B fLF  
MoLF  
HoLF  
HuLF  
MLKPEMIEKLNEQMNLELYSSLLYQQMSAWCSYH. .TFEGAAAFLRRHAQEEMTHMQRLFDYLTDTGNLPRINTVESP .... 
MLSKDI IKLLNEQVNKEMNSSNLYMSMSSWCYTH. .SLDGSGLFLFDHAAEEYEHAKKL IVFLNENNVPVQLTS ISAP  .... 
TAPQVSLARQNYADECESAINEQINVEYNASYvYHSLFAYFDRDNVALKGFAKFFKESSEEEREHAEKLMKYQNTRGGRVvLH~IKNVPSEF  
QSPDKSLARHKFVDDCEAALNEQINVEYNA•YAYHSLFAYFDRDNVALKGFAKFFKESSDE•REHAEKLMEYQNKRGGRvRLQSIVTPLTEF  
SLCRQNYHEECEAGvNKQINMELYASYVYMTMAFHFNRDDVALNGFYKFFLNESEEERQHAIKLMTYQNMRGGRIvLQDISAP . . .  
KTMSSSRARQSFATECENAINKQINvELQAAYDYMAFFTYFDRDDVSFPKAAEFFRKASHEEREHAEKLAKYQNKRVGRvQYSDIKCP. . .  
MSVSQARQNYHAESEAGINRQINMELYASYSYQSMAYYFDRDDVALPGFHKFFKHQSEEEREHAEKLMKYQNKRGGRIVLQDIKKP . . .  
KEFVATVRQNYKENINQLLEQQIQKELAASY IYQAYASYFQKADVSLPGIKKFFSDASSEERDDAQSL IDY INQRGGHvQYDKIDLK. . .  
MTSQvRQNFHQDCEAAINRQINLELYA~YvYLSMAYYFDRDDQALHN~AKFFKNQSHEEREHAEKLMKvQNQRGGRIFLQDvKKP. . .  
MESQIRQNYHHDCERAINRMINMEMFASYTYTSMAFYFSRDDVALPGFAHFFKENSEEEREHADKLLSFQNKRGGRILLQDIKKP . . .  
MVSQVRQNYHSDCEAAVNRMLNLELYASYTYSSMYAFFDRDDvALHNvAEFFKEHSHE•REHAEKFMKYQNKRGGRwLQDIKKP . . .  
MDSQVRQNFHRDCEAAINRb~VNMELYASYTYLSMAFYFDRDDIALHNVAKFFKEQSHEEREHAEKLMKDQNKRGGRIVLQDvKKP. . .  
MATPPSQVRQNYHQDCEAAINRQINLELYA~YVYLSMSYYFDRDDvALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIKKP . . .  
TTASPSQVRQNYHQDAEAAINRQINLELYA~YVYLSMSCYFDRDDVALKN~AKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIKKP . . .  
TTASTSQVRQNYHQDSEAAINRQINLELYASYvYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLaMKLQNQRGGRIFLQDIKKP . . .  
MESQvRQNFHQDCEAGLNRTvNLKFHSSYvYLSMASYFNRDDVALSNFAKFFRERSEEEKEHAEKL IEYQNQRGGRVFLQSVEKP. . .  
TSQIRQNYSTEVEAAVNRLvNLHLRA•YTYLSLGFFFDRDDVALEGVGHFFRELAEEKREGAERLLEFQNDRGGRALFQDvQKP. . .  
SSQIRQNYSTEVEAAVNRLVNLYLRASYTYLSLGFYFDRDDvALEGvCHFFRELAEEKREGAERLLKMQNQRGGRALFQDLQKP. . .  
SSQIRQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELAEEKREGYERLLKMQNQRGGRALFQDIKKP . . .  
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. . L IGEHTKEMLECDLKLEQAGLPDLKAAIAYCESVGDYASRELLED. ILESEEDHIDWLETQLDL IDK IG ..... LEN.YLQSQMDE 
. .RVGQTLREQFEA/bLA IEYEVMSRLKPGI IMCREKQDSTSAVLLEK. IVADEEEHIDYLETQLALMGQLG ..... EEL .YSAQCVSRPPS 
. .R IGQTLREQFEADLAIEYEVMDRLKPAI ILCREKQDSTTATLFEQ. IVADEEKHIDYLETQLELMDKLG .... VEL .YSAQCVSRPPS 
. .R IGQNVKEVLEADLKGEYDARASYKESREICDKLGDYVSKQLFDE.LLADEEGHIDFLETQLDLLAKIG ..... EER.YGQLN2%APADEAE 
.FAEYSSLDELFQETYKHEQLITQKINELAHAAMTNQDYPTFNFLQW.YVSEQHEEEKLFKS I IDKLSLAG. .KSGEGL.YF IDKELSTLDTQN 
.EHKFEGLTQIFQKAYEH•QHISES INNIvDHAIKGKDHATFNFLQW.YVSEQHEEEvLFKDILDKIEL IG . .NENHGL.YLADQYVKGIAKSRKS 
EHVEKGDALYAMEL/•LSLEKLvNEKLLNVHSVADRNNDPQMADFIESEFLSEQVESIKK ISEYVAQLRRvG. . .KGHGV.WHFDQRLLD 
DHFEKGDALYAMELALALEKLVNEKLHNLHGVATRCNDPQLTDF IESEFLEEQGEAINK ISKYVAQLRRVG KGHGV WHFDQMLLEEEA 
PQLSWNSGLHAMQDALDLEKKvNQSLMELVAVGERHRDTHFCDFINNEYLE IQvQSMKKLSDYITNL IRVG. . .NGLGE.YTFDKETLHGESQ 
TKTEFSSLEDAMNTALGMEKAvSKSLLELHEVASKNNDPALADFIESEFLHEQEDAIKQFADYLTETQRvG. . .KGLGE.YLFDKLTLNE 
DRDEWGTGLEAMQVALQLEKSVNQSLLDLHKLCTSHDDAQMADFLESEFLEEQvKSIKELSDYITNLKRvG. . .PGLGE.Y IFDKETLSSSS 
ERSDWKEGLIAFEDTLAIERYVNAQLLDIHKKADDEKDAHLTHILEHEFLEEQvSS INK IAHAITRLRSFE. . .QGSGNNYKLGRVYLRPTPQISH 
EKDEWGSGVEALESSLQLEKSvNQSLLDLHKVCSEHNDPHMCDFIETHYLDEQvKSIKELGDTPDNLRRMGAPQNAMAE.YLFDKHTLGKEST 
ERDEWGNGLEAMQCALQLEKNvNQALLDLHKIASDKVDPHLCDFLETHYLNEQVEAIKKLGDHITNLTKMDAvKNKM2•E.YLFDKHTLG-GQS 
ERDEWGNTLEAMQAALQLEKTVNQALLDLHKLATDKVDPHLCDFLESEYLEEQVKDIKR IGDF ITNLKRLGLPENGMGE.YLFDKHSV.KESS 
ERDEWGNTLEAMQAALQLEKTvNQALLDLHKVGSDKvDPHLCDFLETEYLEEQVKSIKQLGDYITNLKRLGLPQNGMGE.YLFDKHTMGESS 
DRDDWENGLTAMECALHLEKNVNQSLLELHKLATEKNDPHLCDFIETHYLDEQVKAIKQLGDHVTNLRKMGAPKYGMAE.YLFDKHTLGESDS 
DRDDWESGLNAMECALHLEKSvNQSLLELHKLATDKNDPHLCDFIETYYLSEQVKSIKELGDHVTNLRKMGAPEAG~KAE.YLFDKHTLGHGDES 
DCDDWESGLN/~MECALHLEK1q-VNQSLLELHKLATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMGAPESGIA~E.YLFDKHTLGDSDNES 
ERDDWANGLEALQTALKLQK~V-NQALLDLHAVAADKSD~TDFLES~YLSESVETIKKLGDHITSLKKLWSSHPG~.YLFNKHTLG 
~QDEWGKTQEA-MEAAIAkMEKNLNQALLDLHALGSARTDPHLCDFLESHYLDKEVKLIK~GNHLTNLRRvAG~QGSLGE~YLFERLTLKHD 
SQDEWGTTLD/hMKAAIVLEK~LNQ2LLLDLHALGSAQADPHLCDFLESHFLDEEvKLIKKMGDHLTNIQRLvGSQAGLGE~YLFERLTLKHD 
HuLF  AEDEWGKTPDAMKAAMALEKKLNQA-LLDLHALG•ARTDPHLCDFLETHFLDEEVKL•KKMGDHLTNLHRLGGPEAGLGE•YLFERLTLKHD 
89 182 
The table shows primary structures of five bacterial haemoferritins (BFRs), two bacterial non-haem ferritins (FTNs), and examples of ferritins from plants, 
invertebrates and vertebrates. 
Key: BFRs from E. coli (Ec [62]), A. L'inelandii (Av [64]), M. leprae (MI [66]), M. auium (Ma [68]), B. melitensis (Bm [67]); FTNs from E. coli (Ec 
[63]), H. pylori (Hp [66]) and other H-type ferritins from soybean (Soy [54]); maize (Mail [56]), Schistosoma mansoni (Schl and Sch2 [39]), Lymnaea 
stagnalis (soma, Lyml and yolk, Lym2 [38]); salmon (Sail, Sal 2, [474]), bullfrog (BfMF and BfHF [36]), chicken (ChHF [307]), mouse (MoHF [396]), 
horse (HoLF [475]) and human (HuLF [74]). 
For further sequences consult Ref. [37]. The numbers above the sequences correspond to those of the BFRs and those below to HuHF. 
Residues in bold indicate those which have been identified as metal igands (at the ferroxidase centres) in EcBFR [97,175], EcFTN [86] or HuHF [82]. The 
starred methionine is the haem iron axial ligand of BFRs [85,98]. 
Residues appearing in helices in HuHF are shown as D. 
Note that certain sequences contain N-terminal extensions or insertions not shown in the table: N-terminal 'germination' extension, Soy = 
STVPLTGVIFEPFEEVKKSELAVP and Mail = AAGKGKEVLSGVVFQPFEEIKGELALVP; Lym2 has an N-terminal signal sequence MNSVLFLT- 
LAVCSSLAYG and an insertion DACETVMKFVTSDTSGLEEFRDRRMCICGFVATKTINDNCG between residues 88 and 89; MoLF has an 8-residue 
insertion QPAQTGAP between 161 and 162 (HuHF numbering). 
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second in males [39]. Ferritins from chitons and limpets 
[40,41] and from the earthworm Octolasium complanatum 
[42] have been described in some detail. Examples of 
ferritins from fish and insects that have recently been 
characterised are from the rainbow trout [43], from the 
lamprey [44], from larvae of the insect Calpodes ethluis 
[45] and from midgut-epithelial cells by Philaenus pumar- 
ius [46]. Although in vertebrates, ferritins are mainly lo- 
cated in the cytoplasm, low concentrations (123 ng /ml  in 
human males, 56 ng /ml  in females) are also found in 
blood plasma [47]. Insect ferritins are present within the 
vacuolar system, lumen of the endoplasmic reticulum or 
secreted in the haemolymyph [45,46,48]. Chitons and 
limpets have high concentrations of ferritin in the 
haemolymph (0.4 mg/ml  in chitons), where it seems to 
play an iron transport role [40]. Plants store iron as ferritin 
within the plastids, chiefly in tissues which show low 
photosynthetic a tivity [49,50]. It is absent from roots and 
leaves but accumulates in seeds [51]. Its synthesis and 
degradation are developmentally regulated [52]. 
The amino acid (cDNA) sequences of ferritins from pea 
seeds [53], soya bean [54], French bean [55] and maize (2 
sequences with 96% identity) [56] have been determined. 
Ferritins are also found in fungi [57], yeast [58] and in 
bacteria [59-63]. Seven complete amino acid sequences of 
bacterial ferritins are known: m,o of these are from Es- 
cherichia coli [62,63] one each from Azotobacter 
einelandii [64], Mycobacterium leprae [65], Helicobacter 
pylori [66] Brucella melitensis [67] and Mycobacterium 
aL'ium [68]. Partial amino acid sequences have been deter- 
mined for ferritins from Nitrobacter winogradskyi [69], 
Mycobacterium paratuberculosis [70], the cyanobacterium 
Synechocystis [71] and from the obligate anaerobe Bacteri- 
oides fragilis [72]. Except for the latter, for one of the 
ferritins from E. coli designated FTN [63], and for that 
reported for H. pylori (designated PFR (prokaryotic fer- 
ritin) [66] but here referred to as FTN because of its 
similarity to the FTN of E. coli), the ferritins so far 
characterized from microbial sources are haemoferritins. 
They are generally known as bacterioferritins or BFRs. 
Haem contents, as isolated, are usually between about 0.25 
and 0.5 haem per subunit. 
Selected examples of ferritin amino acid sequences are 
given in Table 1, including A. L, inelandii (AvBFR) [64], 
H. pylori FTN [66], BFRs of M. leprae [65], M. acium 
[68], B. melitensis BFR [67] and maize ferritin [56]. For a 
more complete list (but not including the most recent 
sequences), see Andrews et al. [37]. Note that, in animals, 
more than one sequence may be found (e.g., two in 
humans, three in tadpoles). In mammalian ferritins (Fig. 1) 
the two sequences known as H and L show about 54% 
identity, whereas about 90% of H-chain residues and about 
85% of L-chains are identical [37,73,74]. The three tadpole 
and four invertebrate sequences are closer to H-chains of 
mammals (60-70% and 37-69% identities respectively) 
than to their L-chains (50-65% and 31-54%). Plant fer- 
H24Lo 
Hela cells 
Muscle 
Thymus 
Red blood cells 
Brain 
Heart 
Lymphocytes 
Liver 
Spleen 
, @  Serum 
HoL24 
Fig. 1. Schematic diagram of human 'isoferritins' of different subunit 
compositions. Each ferritin subunit s depicted as a 'sausage' and sub- 
units are packed in a symmetrical shell. Twelve of the 24 subunits are 
visible. Mammalian ferritins are composed of two subunits of different 
primary structures, known as H and L. In the diagram stippled subunits 
represent human H-chains and plain subunits, L-chains. H-chain and 
L-chain homopolymers a e shown respectively at the top and bottom of 
the figure, and heteropolymers of descending H content are placed 
between the homopolymers. Coassembly of the two subunit types is 
possible because many of the inter-subunit contact residues are con- 
served, The sources of various ferritins are listed in the right-hand 
column, such that heir average subunit compositions are indicated (e.g., 
muscle ferritin about 20 H: 4 L, liver ferritin about 2-3 H: 22-21 L). 
Most of the data were obtained by immunoassay using H- or L-chain- 
specific antisera [476]. The composition of human brain ferritin was 
measured after subunit separation bygel electrophoresis [477]. The pair 
of molecules in the fourth position indicates that subunits may be 
clustered ifferently in molecules of the same composition. I  vitro 
assembly experiments indicate that dimers are a first assembly intermedi- 
ate and it is likely that these dimers are antiparallel pairs formed by 
association f subunits along their along axes as shown here. It may be 
supposed that H-chains (or L-chains) forming on their polysomes would 
associate into homodimers before co-assembly into heteropolymers, al- 
though there is no evidence for this. 
ritin sequences, aligned with those from animal ferritins, 
are all more similar to mammalian H-chains than to their 
L-chains. Pea seed ferritin, for example, gives 49% iden- 
tity with human H-chain and 40% with human L-chain. 
Bacterial ferritins diverge further from animal ferritins 
being only 22-24% identical to H-chains and 18-21% 
identical to L-chains of mammals, and the two E. coli 
ferritins, BFR (haemoferritin) and FTN show only 14% 
identity to each other [37,75]. However, it is clear that the 
ferritin family of iron storage proteins includes members 
of bacterial origin [37,64,75]. 
Ferritins isolated from mammalian tissues consist of a 
mixture of isoferritins with a range of subunit composi- 
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tions and iron contents (Fig. 1) [73]. Twenty-five isofer- 
ritins of defined composition are possible, with subunit 
ratios: Hz4L0, H23L l H22L2-HoL24, but isoferritins H22L 2 
to H2L22 are heterogeneous given that different distribu- 
tions of subunits may be possible within the shell. In 
general L-rich ferritins are characteristic of organs storing 
iron (liver and spleen) and these ferritins usually have a 
relatively high average iron content (1500 Fe atoms/mole-  
cule or more). H-rich ferritins which are characteristic of 
heart and brain have relatively low average iron contents 
(less than 1000 Fe atoms/molecule).  No H-chain ho- 
mopolymers have been isolated but human serum ferritin 
is devoid of H-chains [76] and an L-chain homopolymer 
fraction has been extracted from horse spleen ferritin [77]. 
Some ferritin subunits have amino acid insertions or 
N-terminal extensions relative to mammalian chains. Plant 
ferritins are synthesized as precursors with an N-terminal 
extension of over 70 residues that is absent from the 
mature ferritin [52-54,78]. The first part of this extension 
is a plastid targetting (PT) sequence (about 40 residues) 
which is lost on entry into the organelle. The second part 
(extension peptide, EP) is lost after molecular assembly 
either in vivo on germination or in vitro during iron 
exchange [78]. Pea seed ferritins, with and without PT and 
EP, have been cloned and expressed in E. coli [79]. 
Assembly to 24-mer was obtained only after PT deletion. 
3.1.2. Three-dimensional structures 
The known three-dimensional structures of ferritins are 
more highly conserved than their primary structures. Each 
of the 24 subunits consists of a bundle of 4 long helices, a 
fifth short helix and a long extended loop (overall dimen- 
sions about 25 × 25 × 50 A3 Fig. 2). The subunits are 
arranged to give a hollow, symmetrical shell with outside 
and inside diameters 125 and 80 A respectively (Figs. 
1-3). X-ray structures have been derived for the following 
ferritins: native horse spleen (HoSF-85% L-chain) [34,80], 
native rat liver (67% L-chain) [81,82], recombinant rat 
L-chain (RaLF) [81,82], recombinant human H-chain 
(HuHF) [82], recombinant bullfrog L-chain (BfLF) [83,84], 
recombinant S. mansoni (type 1, Yewdall, Hirzmann, 
Artymiuk and Harrison, unpublished work), E. coli BFR  
(EcBFR) [85] and E. coli FTN (EcFTN, now in course of 
refinement, Ref. [86] and unpublished work of Hempstead, 
Yewdall, Hudson, Andrews, Artymiuk, Guest and Harri- 
son). The structures are closely similar, e.g., most main 
chain atoms of human H, rat L, horse L, S. mansoni 1 and 
EcFTN (H) apoferritins uperpose within about _+ 1.0 ,~. 
The root mean square difference in backbone atomic posi- 
tions of HuHF and BfLF is 0.97 A [83] and that for 156 
equivalenced alpha carbons of EcBFR and horse spleen L 
ferritin is 2 A (Dautant, Meyer, Yariv, Kalb (Gilboa), 
Frolow and Precigoux, personal communication). There is 
no X-ray structure as yet of a plant ferritin, but computer 
modelling suggests that these ferritins can adopt conforma- 
tions resembling those of mammalian ferritins [53]. 
Each apoferritin (iron-free) molecule is assembled from 
24 structurally equivalent subunits. In mixed subunit 24- 
mers (heteropolymers) H- and L-subunits have the same 
conformations and the many identical or similar residues 
in H-H, H-L and L-L inter-subunit contact regions enable 
the formation of heteropolymers with the complete range 
of subunit compositions. It has been proposed, however, 
that like chains cluster preferentially within the polymer 
[87] and this may apply particularly to dimer pairs. The 
apoferritin shell is notable for its stability to heat (treat- 
ment for 5 -10 min at 70°C is routinely used as a prepara- 
tive step) and to urea or guanidinium chloride. The large 
numbers of intra- and inter-subunit salt bridges and hydro- 
gen bonds contribute to this stability. Features of the 
c 
A 
D 
C 
! 
Fig. 2. Ribbon diagrams of ferritin subunits howing conservation f subunit fold. (a) HuHF; (b) EcFFN; (c) superposition f HuHF (black) and BfLF 
(grey). Subunits are folded as 4-helix bundles with a fifth short helix lying at an angle of about 60 ° to the bundle axis. Identities and similarities inamino 
acid sequences are respectively: HuHF and EcFTN, 24% and 51%; HuHF and BfLF 61% and 86%; EcFTN and BfLF, 25% and 54%. HuHF structure as in 
[82], EcFTN as in [86] and BfLF as in [84]. The stippled area in (a) indicates a hydrophilic region which is detailed in Fig. 6. We thank P.D. Hempstead for 
(a) and (b) and N.M. Allewell for (c). Helices in (a) and (b) are labelled A, B, C, D, E. Accession umber for HuHF coordinates in Brookhaven Protein 
Data Base is 1HFA. 
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human recombinant H-chain ferritin (HuHF) and other 
ferritins are shown in Figs. 1-8. 
3.1.3. Shell assembly, inter-subunit channels and cavit3, 
In the assembled molecule the 24 subunits are related 
by operation of 4-fold, 3-fold and 2-fold symmetry axes 
(432 symmetry, Fig. 3). Anti-parallel subunit pairs with 
their long apolar interfaces around 2-fold symmetry axes 
are the likely first assembly intermediates (Fig. 3c) 
[34,88,89]. Subunits pack tightly together except that at 
3-fold axes there are narrow channels traversing the shell. 
Residues around the 3-fold axes are predominantly hy- 
drophilic in the ferritins of higher organisms (Fig. 4). In 
vertebrate and plant ferritin sequences, side chains lining 
the narrowest parts of the channels at the cavity end are 
highly conserved, namely 3 (symmetry-related) aspartates 
(seq. No. 131) and 3 glutamates (No. 134). These residues 
bind metals (Cd 2+, Zn 2+, Tb 3+ or Ca 2+ [34,80,82,90]) 
C, 
d~ 
J 
a 
d 
Fig. 3. Subunit packing in molecules of EcBFR. Subunits are depicted as 
ribbon diagrams. Views are from the outside of the molecule down, (a) 
4-fold, (b) 3-fold and (c) 2-fold symmetry axes. For clarity, only the 
upper subunits are shown. Subunit arrangements in other ferritins are very 
similar. Note that subunits pack around 2-fold axes as anti-parallel pairs, 
which can be seen most clearly in (b) and (c). Such pairs are thought to 
be the first intermediate formed uring subunit assembly in horse spleen 
ferritin [34,88,89]. A schematic general view outlining the positions of 
subunits in relation to the symmetry axes is shown in (d). Drawings based 
on structure described in[85] and coordinates in Brookhaven Protein Data 
Base accession umber IBCF. Note that the 12 haem groups of EcBFR 
are not shown in this diagram, but they are situated between two subunits 
at the 2-fold axis interface in positions imilar to those depicted for the 
protoporhyrin IX derivative of horse spleen ferritin in Fig. 7. In EcBFR 
the haem Fe atoms are bound by two symmetry-related methionines and 
the haem is tightly wedged between the subunits, with which it makes 
more than 100 Van der Waals contacts. The propionyl side chains of the 
haem project into the cavity (as in Fig. 7), enabling them to interact with 
the mineral of the core. 
and the 3-fold channels have been proposed as the main 
entry route for iron [90-96] and as sites of Fe(II) oxidation 
[90-92,94]. However, these residues are not both con- 
served in some invertebrate sequences [37-39]. EcFTN 
and H. pylori FTN (HpFTN, as aligned) have several 
hydrophobic residues near the 3-fold interface and Asn and 
Gln in place of Asp 131 and Glu 134 respectively (Fig. 4) 
[37,66]. No metals are found at the 3-fold interface in 
EcFTN [86]. EcBFR has a hydrophilic 3-fold interface 
involving Asp 109, Asp 118 and Arg 117 [85,97] like that 
predicted from sequence alignment and modelling [98]. 
The 4-fold axis interface is highly hydrophobic in mam- 
malian L ferritins, being lined by 12 leucine residues. In 
H-chains there are four histidines at the cavity side and 
usually four methionines (leucines in HuHF) at the outer 
surface and BfLF is similar. In invertebrates, plants and 
bacteria there is more variation, especially in the latter. In 
pea seed ferritin, as modelled, residues butting on to the 
4-fold axes are eight histidines and four arginines. In 
EcBFR [97] the 4-fold channels are hydrophilic with Ash 
148 and Gln 151 pointing towards the symmetry axes. The 
4-fold axis regions of HuHF and EcBFR are shown in Fig. 
5. In the medium resolution structure of horse spleen 
ferritin there appeared to be small gaps or channels passing 
through the shell at the 4-fold axes. However, the refined 
high resolution structure of HuHF shows very little space 
around these axes (Fig. 5), as has also been reported for 
recombinant BfLF [83]. In EcBFR the interface is less 
tightly packed and there is space for a water molecule to 
pass through (Fig. 5c). 
All ferritin molecules contain an approx. 80 A diameter 
iron-storage cavity. Unexpectedly, residues on this cavity 
(mineralizing) surface are not highly conserved. There are 
differences on the cavity surface residues of mammalian 
H- and L-subunits, with L-chains showing a higher pre- 
ponderance of carboxylates than H-chains [151] (Table 2). 
Plant ferritins have arrays of carboxyl groups resembling 
those of L-chains [53,99], but the cavity surfaces of bacte- 
rial ferritins seem to be very different (Table 2). 
3.1.4. Metal and haem binding 
Ferritin subunits fold so that at each end of the 4-helix 
bundle there is an apolar 'core' [80]. However, all subunits 
have central hydrophilic regions, Figs. 2 and 6. In the 
L-subunit of horse (HoLF) and rat this region contains a 
salt bridge (see Fig. 8) and a similar (modelled) salt bridge 
in human L-chains contributes tability [82,100]. In BfLF 
the region contains bound water molecules, but no salt 
bridge, Fig. 6d, and HuHF has metal-binding sites in the 
same region [82], Fig. 6a and Fig. 8. Metal ligands and 
some nearby residues are highly conserved in H-chains of 
animals and plants and in EcFTN [37,39,53,75] (Fig. 6a,b 
and Fig. 8, and Table 1) and HpFTN [66] the metal ligands 
are the same as in HuHF except for the substitution of 
Glu61 by Glu144. Direct confirmation that these sites bind 
iron has recently been obtained for EcFTN [86] (Fig. 6c), 
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and a third iron has also been identified at a nearby 
position. In the haem-containing BFRs five of the residues 
are conserved and are now known to bind metal. Although 
the actual metal has not been identified, it is likely to be 
Mn 2+ which is present in the crystallising solution [85,97] 
(Fig. 8). This highly important functional site is associated 
with ferroxidase activity (see below). 
BFRs, as isolated, contain iron-protoporphyrin IX with 
unique bis-methionine co-ordination [101,102]. Modell ing 
of haem-binding sites [98] tested by mutagenesis [103] 
suggested that it is bound at an inter-subunit site near to 
the cavity surface at 2-fold axis positions with two Met 52 
residues of neighbouring subunits as haem iron ligands. 
The recently reported 2.9 .~ resolution structure of EcBFR 
confirms the similarity of BFR to mammalian ferritins and 
places the haem group at the 2-fold axis interface as 
predicted [85,97]. An intriguing new observation is that 
protoporphyrin IX can also bind to HoSF at the same 
interface and in a similar inter-subunit cleft (Fig. 7) [104]. 
HoSF was co-crystall ised with Sn-protoporphyrin IX, but 
the Sn was lost on binding to the protein. Previously a 
spectroscopic analysis of haem bound to horse spleen 
apoferritin indicated bis-histidine ligation of the haem iron 
and a model with haem bound near to 3-fold axis positions 
was proposed [105]. Possibly the haem was bound with 
bis-arginine ligation in the 2-fold cleft. Binding of proto- 
porphyrin in this position raises the question as to how it 
reaches this site. Is the shell sufficiently flexible to allow 
passage of the flat ring between subunits through the 
hydrophobic interface or does the shell dissociate? Whether 
the binding of protoporphyrin IX to vertebrate ferritins has 
any physiological significance remains another interesting 
but unanswered question. It may be noted that Arg 63 of 
the binding pocket, which lies against the flat protopor- 
phyrin ring, is conserved in all known sequences of verte- 
brate ferritins with one exception, namely BfLF [36,37]. 
Arg 63 is also present in ferritins of invertebrates and 
plants, but not in the non-haem ferritins of bacteria [37,66]. 
EcFTN, but not HpFTN, has Met 52 equivalent o the 
haem-iron ligand of EcBFR. None of these ferritins con- 
tains haem as isolated, however. The presence of haem 
seems to facilitate reductive iron release from both verte- 
brate [106] and bacterial [107] ferritins, but it is without 
major effect on Fe(II) oxidation rates in EcBFR [103] (see 
below). The overexpressed haem-free variant EcBFR- 
M52H contains more iron, as isolated, than the equivalent 
a 
b 
/ 
Fig. 4. Intersubunit interface around the 3-fold axis in various ferritins viewed from inside the molecule. (a) BfLF; (b) HuHF; (c) EcF'I~. In (a) solvent 
molecules are in dark grey and side chains of one subunit are labelled. In (b) Aspl31 and Glu134 are in positions equivalent tothose labelled D127 and 
El30 in (a). Note the central Ca 2+ ion which is bound by the six carboxylates. HuHF was crystallised from CaCL 2. In (c) the interface is very different 
with no metal ions or water molecules obvious. Asn and Gin replace the Asp 127 and Glu 130 and Aspl 31 and Glu 134 of (a) and (b) respectively and point 
away from the 3-fold axis, whereas, incontrast, Met122 and Phel30 point toward the axis. The residue numbers used for EcFTN are based on its sequence 
alignment to HuHF, Table 1. Those for BfLF are actual numbers (add 4 to align with HuHF). We thank N.M. Allewell for (a) and P.D. Hempstead for (b) 
and (c). 
~ 0 m 
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wild-type EcBFR, possibly indicating an effect of haem on 
iron release in vivo [103]. 
3.2. Ferritin iron-cores 
Unlike the highly conserved ferritin protein shell, the 
structure of ferritin iron-cores is quite variable due, in part, 
to differences in composition, notably the content of inor- 
ganic phosphate [99,108-111]. Iron-core structures (see 
Ref. [112] for review) have been studied principally by 
X-ray or electron diffraction [109,111,113,114], electron 
microscopy [41,99,109,115-117] and MiSssbauer spec- 
troscopy [41,44,99,110,111,117-124] and, to a less extent, 
by EXAFS [125-127]. Native cores in horse [113,114], 
human [109] and rat [111] ferritins are ferrihydrite (5 
FezO 3 -9H20 [ 128]), with varying degrees of crystallinity, 
as judged by the above techniques. Each Fe(III) atom is 
surrounded by approx. 6 oxygen atoms at a distance of 
1.93 A [125-127]. Most native ferritins contain some 
inorganic phosphate, while giving ferrihydrite diffraction 
lines, e.g., horse spleen which has on average about 1 P 
per 10 Fe atoms [108]. The iron-cores of Pseudomonas 
aeruginosa and A. vinelandii BFRs are essentially hy- 
drated ferric phosphate with P:Fe ratios of between 1 : 1 and 
1:2 [109,110]. In pea seed (Pisum sativum) ferritin the 
ratio is 1:2.8 [99]. In all three cases, the iron cores are 
amorphous. On the other hand, ferritins isolated from 
iron-loaded rat livers [111], from the haemolymph of the 
limpet Patella laticostata [41 ], and from the chiton Acan- 
thopleura hirtosa [41] have iron-cores of limited crys- 
tallinity, even though they contain very little phosphate 
(P:Fe respectively for rat, l impet and chiton being 1:40, 
1:44 and 1:36). It is likely that core crystallinity is influ- 
enced by the rate of iron deposition as well as by the 
composition of the medium. Also, ferritins which had 
amorphous iron-cores as isolated (e.g., from A. vinelandii 
or Pisum sativum) can give crystalline ferrihydrite cores 
on reconstitution [99,117]. The bulk mineral structure 
seems to show no preferred orientation with respect o the 
protein shell [113], even though the groups on its cavity 
surface are thought o be important for its nucleation (Ref. 
[83] and see below). As isolated, ferritins may contain just 
a few Fe atoms or up to about 4500. Ways in which the 
presence of inorganic phosphate may affect core develop- 
ment in vitro are discussed below. Phosphate appears to 
bind to the surface of the growing core and then some of it 
to become incorporated as more iron is added. A novel 
non-ferrihydrite small cluster of unknown structure, which 
contains no phosphate, has recently been observed by 
MiSssbauer spectroscopy at an early stage of core reconsti- 
tution in EcFTN [124]. 
4. Iron storage processes 
A part of a dose of 59Fe injected into a rat as labelled 
ferric ammonium citrate or iron dextran will later be found 
in the liver as soluble cytosolic ferritin [129-133]. The 
steps by which this iron is processed have not been fully 
elucidated. Some of the iron delivered by transferrin also 
finds its way into cell-sap ferritin. Transferrin is taken up 
into endocytic vesicles by receptor-mediated ndocytosis 
[19,134,135]. Release of its iron within the endosome is 
probably mediated by protons and facilitated by binding 
the receptor [136-138]. Neither the chemical form in 
which iron is delivered to ferritin molecules in vivo nor its 
intracellular donor is known, but storage involves gradual 
accumulation by binding of iron to core particle surfaces 
[130,139]. Except for vertebrate L-chains, all ferritins se- 
quenced contain conserved residues that have been associ- 
ated with ferroxidase activity, as described below. This has 
led to the tacit assumption that iron uptake into ferritin is 
an oxidative process starting from Fe(II) and that the 
oxidant is dioxygen, although other physiological oxidants 
have been considered. 
4.1. Iron-loading of  apoferritin shells - the catalysis o f  
Fe(ll)-oxidation by apoferritin in vitro 
Although ferric citrate is probably one of the low 
molecular weight iron complexes of the cell sap, attempts 
to load apoferritin shells with ferric citrate (or with other 
Fe(III) compounds) in vitro have failed [140] unless a 
reductant like ascorbate is present [141]. Iron supplied as 
an Fe(II) salt under oxidising conditions is taken up by 
apoferritin in vitro, and is oxidised and converted into 
ferrihydrite in its cavity to give a product closely resem- 
bling natural ferritin [142]. Consequently most studies of 
ferritin functionality have been based on its capacity to 
oxidise Fe(II) and incorporate it aerobically at neutral pH 
in the absence of natural iron binding molecules uch as 
citrate, phosphate or amino acids. Under these largely 
Fig. 5. Intersubunit interface around a4-fold axis in HuHF and EcBFR viewed from outside the molecule. (a): 4 HuHF subunits around a4-fold symmetry 
axis with the atoms in the vicinity of the axis shown as spheres drawn with Van der Waals radii. Thus residues are in close contact with only a very narrow 
'channel' around the axis. (b): enlargement of central region of (a); white spheres represent carbons and grey spheres oxygen and nitrogens; (c): equivalent 
regions of EcBFR; (d): detail of 4-fold interface of HuHF showing three residues of each subunit (two leucines and a histidine) pointing toward the 4-fold 
symmetry axis; (e): detail of 4-fold interface of EcBFR. The character of this interface differs from that of (d). Only two residues of each subunit 
(asparagine and glutamine) point oward the axis. The 4-fold interface in EcBFR is less tightly packed and more hydrophilic than that of HuHF. (Compare 
(b) and (c) and (d) and (e)). It can also be seen by comparing d and e and Fig. 2a) and Fig. 3a) that the E helices, which pack around the 4-fold axes, are 
much shorter in EcBFR than in HuHF. 
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unphysiological conditions Fe(II) oxidation is un- 
favourable (in the absence of ferritin), but it is driven 
forward by the hydrolysis of the Fe(III) and its precipita- 
tion as insoluble ferric oxyhydroxide: 
4Fe 2++ 02 + 4H += 4Fe 3+ + 2H20 
4Fe3++ 8H20 = 4FeOOH$ + 12H + 
4Fe 2÷ + 02 + 6H20 = 4FeOOH$ + 8H + 
Iron-core formation within ferritin is much faster than 
formation of ferric oxyhydroxide under protein-free condi- 
tions [142-147]. This is due, in the first instance, to 
catalysis of Fe(II) oxidation by apoferritin [96,143-149], 
but binding to residues within the cavity may lower the 
activation energy of nucleation of the oxidised product 
[142,150]. The protein also influences the form of oxyhy- 
droxide produced. Thus the mineral formed within ferritin 
is ferrihydrite, whereas either e~- or ~-FeOOH (goethite or 
lepidocrocite) is produced in the absence of the ferritin 
shell under otherwise identical conditions [114]. Although 
considerable variation in cavity surface residues is toler- 
ated (Table 2), the efficiency of ferrihydrite nucleation 
probably depends on the distribution of cavity surface 
charges [150,151]. In EcFTN, the early non-ferrihydrite 
a 
B ~ ~  A 
b 
:?" C 
cl 
Helix D ~ H ~  elix 
C 
E 136 
~ .elix A 
Fig. 6. Central hydrophilic region of ferritin subunits. (a) HuHF and (b) EcFrN, viewed from similar directions, showing the conserved residues (Glu 27, 
Tyr 34, Glu 61, Glu 62, His 65, Glu 107 and Gln 141) in the central region of the 4-helix bundle (see (c)) for residue numbers); (c): stereodiagram of
EcFTN derivative obtained by soaking a crystal with (NH4) 2 Fe(SO4) 2. Three Fe atoms (grey spheres) are found in each subunit, a pair (Fel and Fe2, 
separation 3.8 A) in the central region and a third Fe atom (Fe3) on the inside surface bound by Glu 61, Glu 140 and Glu 144 (numbers as aligned to 
HuHF). Note that residue 144 is alanine in HuHF. In a different orientation, Glu 144 can ligate the upper Fe atom of the diiron pair. Data from Ref. [86]; 
(d) BfLF. Many of the residues of HuHF and EcFTN are now changed (numbers as in L-ferritins - add 4 to equivalence to HuHF). The grey spheres 
represent water molecules. Courtesy of N.M. Allewell. 
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Table 2 
Acidic and basic residues on the inner surface of mammalian ferritins 
compared with equivalent residues on some other ferritins 
Res. No. Mam H Mam L S.mal a PS b EcFFN EcBFR 
50 N G G G G R 
52 A C /G/S  Y A A N 
53 K H K K A D 
54 Y F F F F V 
57 H E N E R H 
58 Q L E S H E 
61 E E E E E D 
64 E E Q E T K 
68 K R K K R R 
136 H H/Y  E E - - 
140 E E /K  I E E D 
147 E K K K L W 
171 D E D D D A 
176 G K H H T E 
The residues of columns 2 and 3 are conserved unless otherwise indi- 
cated. C-terminal residues not included. The residues in the last two 
columns are according to the alignment of Table 1. 
a S.mansoni ferritin type 1. 
b Pea seed ferritin aligned according to Ref. [53]. 
Fig. 7. Inter-subunit nterface around 2-fold axis in protoporphyrin IX 
derivative of HoSF. (a) Part of shell with inside surface on the left and 
outside surface on the right; (b) subunit dimer showing protoporphyrin IX
on 2-fold axis, viewed from the inside of the molecule. Based on 
coordinates in Brookhaven Protein Data Base, accession umber 1 HRS 
and Ref. [104]. 
product of iron core reconstitution, found by MSssbauer 
spectroscopy, may reflect a unique distribution of amino 
acid residues, although this novel cluster accounts for only 
a small part of the iron (the bulk is ferrihydrite) [123,124]. 
A large amount of work aimed at understanding iron- 
storage mechanisms has been carried out over the last 20 
years, mainly in vitro. Experimental results are often diffi- 
cult to interpret because of the many binding sites compet- 
ing for iron within the protein subunit, on the cavity 
surface and at intersubunit interfaces. Traversal of the 
protein shell, Fe(II) oxidation, Fe(III) migration, ferrihy- 
drite nucleation and iron-core growth can occur simultane- 
ously at different sites in the same or different molecules 
and this leads to both intra- and inter-molecular competi- 
tion for iron. A tendency towards 'all-or-none' distribution 
was noticed in early reconstitution experiments and a 
'crystal growth' model was formulated [142]. As originally 
proposed, this involved the following stages [142,144]: 
first Fe(II) is bound and oxidised at catalytic entres on the 
protein, next Fe(III) clusters form in the cavity which yield 
stable nuclei of crystalline mineral (ferrihydrite) and, lastly, 
these nuclei provide a second (growing) surface onto 
which Fe(II) can be deposited and oxidized. Thus molecules 
that had nucleated would take up iron faster than those 
which had not, providing an important new driving force 
for iron sequestration. An alternative proposal was that all 
Fe(II) entering the ferritin molecule is catalytically oxi- 
dised by the protein before reaching the cavity [145,152]. 
Recent studies of Fe(II) oxidation kinetics with horse 
spleen apoferritin and with HuHF which involved mea- 
surements of oxygen consumption [149,153-156] imply 
that the latter situation prevails at low Fe(II)/protein ratios 
( < 50 Fe atoms/molecule) when oxidation on the protein 
shell is rate-limiting. Under other conditions, however, 
there is evidence that once a core is formed, Fe(II) can be 
bound and oxidised on its surface. In summary: (1) apofer- 
ritin loses its initial specificity for 0 2 as oxidant when an 
iron-core is present [155]; (2) many more Fe(II) binding 
sites are present in ferritin than in apoferritin [120,157]; (3) 
the stoichiometry of Fe(II) oxidation increases from about 
2 Fe(I I) /O 2 at low Fe(II)/apoferritin up to about 4 
Fe(I I ) /O 2 at higher ratios or when Fe(II) is added to 
ferritin [ 149,156, 158-160]; (4) a mixed valence Fe3 +_Fe2 + 
species giving a g = 1.87 EPR signal is generated by the 
addition of 120 Fe 2+ to 18 Fe3+-ferritin or by the partial 
oxidation of 120 Fe 2+ [161,162]; (5) when 4 
57Fe(II)/molecule is oxidised by ferritin, 77% of the 
Fe(III) is attached to the core at 1 min and only 23% to the 
protein, but when the Fe(II) is added to apoferritin most of 
the iron is found on the protein and very little in iron-core 
clusters at early times, [163]; (6) after the early production 
of small Fe(III) clusters, the rate of Fe(III) deposition 
increases [142,147]. Kinetic analysis of Fe(II) oxidation in 
horse spleen ferritin and in HuHF indicates that the rela- 
tive contributions of sites on the protein shell and on the 
iron-core depend on the amount of Fe(II)/molecule added, 
the amount of iron already present and the number of 
catalytic sites (H-chains)/molecule [ 124,149-156]. Obser- 
vations (5) and (6) could also be explained if the stable 
Fe(III) clusters exerted a 'pull' on protein-bound Fe(III) by 
virtue of the greater thermodynamic and kinetic stability of 
cluster Fe(III). Thus the crystal growth hypothesis can be 
re-formulated to include the proposal that stable ferrihy- 
drite nuclei in the ferritin cavity can provide surfaces for 
deposition of iron both as Fe(III) and Fe(II). In vivo it 
could be important for ferritin to accept iron as Fe(III). 
Since the determination of apoferritin's three-dimen- 
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sional structure [34,80-82], work has focused on (a) the 
location of the catalytic sites, (b) the mechanism of cataly- 
sis of Fe(II) oxidation and (c) subsequent steps leading to 
the clustering of Fe(III) atoms and the generation of 
ferrihydrite. It was first proposed that Fe(II) was bound 
and oxidised in the 3-fold inter-subunit channels [90-94]. 
The stoichiometry of binding of several metals (e.g., Cd 2+, 
Tb 3+, Mn 2+ and Fe 2+) of about 0.3 (or, in some cases, 
0.67) per subunit and the competition by Fe 2+ and Fe 3÷ 
for the other metal sites seemed to support such a hypothe- 
sis [34,35,80,90,91,95,120] and led to the conclusion that 
Fe 3-- must migrate from such sites. Study of the effects of 
modifying a cysteine residue (no. 130) close to the 3-fold 
channels on Fe 3÷ EPR signals [92], or of iron on a 
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spin-label attached to this residue [94] were interpreted as 
implicating these channels as iron-binding entry and oxida- 
tion sites. These experiments were carried out with horse 
spleen apoferritin, which contains 85-90% L-chains. Elec- 
tron-nuclear double resonance [164] and multifrequency 
electron spin-echo envelope modulation [165] measure- 
ments reveal the presence in horse spleen ferritins of a 
nitrogenous ligand (probably histidine) as well as car- 
boxyls and a water molecule bound to VO2- /Fe  2+. How- 
ever, when it became evident that H-chains, not L-, are 
responsible for the catalysis of Fe(II) oxidation, the likeli- 
hood of direct 3-fold channel involvement diminished, 
since the channel residues are largely conserved in both H- 
and L-subunit types of vertebrates. Moreover, although 
EcFTN also catalyses Fe(II) oxidation, its 3-fold channels 
do not bind metals [86,124], Fig. 4c. 
4.2. The catalyt ic  sites on H-chains:  the fer rox idase  cen- 
tres 
Much of the recent work leading to new understanding 
of Fe(II) oxidation by apoferritin has been on recombinant 
ferritins containing a single subunit type. First, the cat- 
alytic activity has been associated, not with L-chains, but 
with H-chains,  in human ferrit in [96 ,124,146-  
148,150,151,156,166-168], in bullfrog ferritin [154,169] 
and in the H-type chains of pea seed [79] and both E. col i  
ferritins [124,170]. Second, a metal centre identified by 
X-ray analysis of human H-chain homopolymers, but ab- 
sent from L-ferritin [35,82] (Figs. 6 and 8) has been 
implicated by site-directed mutagenesis. Thus the substitu- 
tion of residues at this centre (E27A, Y34F, E62K + H65G, 
E I07A and Q141E) leads to a diminution of ferroxidase 
activity [37,96,124,146-148,150,151,167,171,172]. Third,
a p~-oxo-bridged Fe(III) dimer found to be an early oxida- 
tion intermediate in horse spleen apoferritin by Mossbauer 
spectroscopy is now known to be H-chain-specific, to be 
associated with ferroxidase activity and to require ferroxi- 
dase centre ligands for its formation [124,146,148,163,171] 
(Table 3). An important feature of the data in Table 3 is 
that even with only 10 Fe(II) added, up to 80% of the iron 
is in ix-oxo-bridged Fe(III) dimers at 1 min after Fe(II) 
addition, indicating that dimer formation is a highly coop- 
erative process. The p:oxo-bridged Fe(III) dimers can also 
be observed by UV difference spectroscopy [171]. Within 
under 30 s of adding Fe(II) to apoferritin in air an absorp- 
tion spectrum appears (maxima about 305 and 345 nm) 
that is similar to those of the Fe(III) i.~-oxo-bridged dimers 
of ribonucleotide reductase and met-haemerythrin as well 
as several model complexes [173]. 
In ferritin, an important property of the dimers for the 
iron-storage process is their relative lability. Both 
M~Sssbauer [96,124,148] and UV spectroscopic data [171] 
show that some of the dimers dissociate within about an 
hour of their formation, although it is uncertain how this 
dissociation is brought about. Dimers are partially replaced 
by monomeric Fe(II1) and later by Fe(III) clusters and the 
distribution of Fe(III) amongst hese species depends on 
pH, time and numbers 
the monomeric Fe(III) 
3-fold channels [96], 
ferroxidase centres to 
of Fe added [96,124,148]. Some of 
so produced has been located in the 
and it may be guided from the 
these channels by groups on the 
protein shell [96]. This implies that there is communication 
between the channels and the ferroxidase centres in verte- 
brate ferritins. However, this does not apply to EcFFN, 
which binds Fe(III) atoms at the putative ferroxidase cen- 
tre Fig. 6 but none in the 3-fold channels, which lack 
suitable ligands [86] (Fig. 4c). 
Evidence for a three phase mechanism corresponding 
Fe(II) binding, catalytic Fe(II) oxidation and core forma- 
tion has been derived for EcBFR from EPR and visible 
spectroscopy and stopped-flow kinetic data [174]. Fe(II) 
was added aerobically and its binding to EcBFR was 
monitored as a perturbation of the 380-425 nm region of 
the haem absorption spectrum. Maximum absorbance 
change was found with the binding of 50 Fe atoms/mole-  
cule (2 Fe( I I ) /subuni0,  which occurred without concomi- 
tant haem reduction. This was the fastest observed phase 
with t l /2  ~ 50 ms. Non-haem Fe(II) oxidation, which was 
monitored at 340 nm, showed two distinct phases. The first 
(phase 2 of the overall process) was complete within a few 
seconds and also saturated after addition of 50 Fe(II) 
a toms/BFR.  Phase 2 was interpreted as oxidation of two 
Fe(II) atoms at the ferroxidase centres. This conclusion 
Fig. 8. Schematic drawings of the dinuclear metal sites of three H-type ferritins compared with similar sites in ribonucleotide r ductase, methane 
monoxygenase and haemerythrin a d with the equivalent regions of two L-type ferritins. The dinuclear i on sites of ribonucleotide r ductase, methane 
monoxygenase and haemerythrin are from their crystal structures (respectively Refs. [81,182,185,183,184]). The different disposition of ligands in 
haemerythrin with respect to the 4-helix bundle places it in a separate class of diiron proteins (class 1) from that of ribonucleotide reductase and methane 
monoxygenase (class 2). The ligands and ligand positions of the dinuclear metal site in EcBFR clearly place this ferritin in class 2. The diiron site of 
EcBFR is based on the crystal structure inwhich the metal ions are likely to be Mn(II) [85]. Hence this arrangement, with double carboxylate bridging, is 
expected for the diferrous derivative of EcBFR. In contrast, he dinuclear site shown for ribonucleotide r ductase, which has one carboxylate and one 
-oxo-bridge corresponds to the diferric form [ 182]. The diiron site for EcFTN is based on the crystal structure of an iron-containing derivative [86] (see Fig. 
5c)). Note that Glu 127 of EcBFR is replaced by Gin 127 in EcFTN and His 130 is replaced by Glul30, thus maintaining four carboxylate ligands. HuHF 
also has Gln 141 (equivalent toGin 127 of Ec FTN), but Ala 144 replaces Glu 130 and another carboxylate, Glu 61, can act as an alternative ligand of Fe2. 
In BfLF and HoLF (residues numbered as in HuHF) there is further divergence in sequence and these ferritins do not form the dinuclear sites characteristic 
of the H-ferritins. Instead, in BfLF, there is a network of hydrogen bonds involving the residues shown and three water molecules (not shown here, but see 
Fig. 6d), and in HoLF, Lys 62 forms a salt bridge. Ala144 of HuHF is replaced in BfLF by threonine and in HoLF by leucine. 
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was supported by the observation of EPR signals ascribed 
to 22 [Fe(II) Fe(II) NO] dimers per BFR molecule, when 
50 Fe(II) was added to apo-BFR anaerobically in the 
presence of ascorbate followed by NO [170] and by the 
low oxidation rates observed with ferroxidase centre vari- 
ants E17A, E51A and E94A (see Fig. 8) [175]. The third, 
slowest, kinetic phase, which corresponds to growth of the 
iron core, took up to 80 min to complete and was consid- 
ered to represent Fe(II) oxidation on iron-core surfaces. 
Recent studies with haem-free variants indicate that the 
rate of Fe(II) oxidation (phase 2) is not diminished in the 
absence of haem, but is slightly enhanced [103]. 
result from two-electron oxidation in an Fe 2+ pair. Pair- 
wise oxidation has also been indicated by recent stopped- 
flow kinetic data [172]. 
In an alternative oxidation scheme [149,156], (b), a 
single Fe 2+ atom is bound to the protein (P). It is then 
oxidised without the dissociation of the superoxide so 
produced. A second Fe z+ is then bound and oxidised with 
the net result that peroxide is produced (as in the first 
scheme): 
(b) two successive 1-electron oxidations. 
Fe 2+ 
P-FeZ++ 0 2 ~ P-Fe3+-O~ - ~ P-Fe3+-O~--FeZ+~ 
4.3. The mechanism of  Fe(l l)  oxidation at ferroxidase 
centres 
Two alternative schemes for Fe(II) oxidation have been 
considered. In the first, (a), two Fe 2+ atoms are bound to 
the protein (P) in close proximity allowing the formation 
of an OH- bridged Fe 2+ dimer. 02 binds to one of the 
Fe z+ atoms allowing oxidation of both of them with 
concomitant formation of H202 [171]. 
(a) 2-electron oxidation 
Fe  2+ 
P-FeZ+-H20 ~ P-Fee+-HzO-Fe2+-p 
P-Fe2+-OH--Fe 2+ + H ÷ o: P_Fe2 +_OH-_Fe 2+ (-Oz)-P 
H + 
P_Fe3+_O2-_FeS+_p + HzO 2 
Variants of this scheme may be envisaged in which 
oxidation of the two Fe 2+ occurs without prior formation 
of an OH-  bridge between them, but with bridging either 
through a water molecule or through dioxygen itself. The 
cooperativity seen for dimer formation (Table 3) could 
P-Fe 3 +-0 2- -Fe 3 + H_~o P-Fe 3 +-O 2 -_Fe 3 + + H 202 
This scheme was based on kinetic studies of horse 
spleen ferritin [149] and of HuHF [156] which indicated 
that the reaction was first order in both iron and oxygen. 
However, rate measurements made with an oxygen elec- 
trode may be misleading because of its relatively slow 
response compared with rates of Fe(II) disappearance mea- 
sured in a stopped-flow spectrometer [172]. 
The oxo bridge derives from water in the first scheme 
and from dioxygen in the second. No evidence has yet 
been obtained for the origin of this oxygen in ferritin. 
Recent Resonance Raman experiments using ~SO 2 indicate 
that in ribonucleotide r ductase, but not in stearoyl-ACP 
desaturase, the bridging O is derived from dioxygen 
[176,177]. After oxidation in ferritin (by either scheme) 
splitting of some of the dimers is envisaged, e.g., 
H + 
P-Fe 3 + + O z--Fe 3 +-P ~ P-Fe 3 +-OH -Fe 3 +-P 
HzO 
--+ P_Fe3+_OH - + HzO-Fe3+-P 
Table 3 
MiSssbauer analysis of products of aerobic oxidation i presence ofvarious ferritins 
Sample Fe/mol a tf ~ %Fe(II) % Fe(III) species 
Monomer Dimer Cluster Magnetic cluster 
apo-rHuHF 10 1 min 
10 3h 
12 1 min 
12 24 h 
apo-HoSF 12 1 min 
12 24 h 
apo-rHuHF 34 1 min 
apo-EcPTN 34 1 min 
apo-rHuLF 34 3 min 
apo-rHuLF 34 30 min 
apo-rHuHF (E27A) 34 1 min 
apo-rHuHF (E107A) 34 30 min 
40 
39 
35 
6 78 
36 35 
26 64 
20 50 
19 25 
6 78 
22 30 
10 
16 
29 19 
10 
30 10 
56 28 
100 92 
16 n.d. 
48 n.d. 
50 n.d. 
100 n.d. 
61 n.d. 
49 n.d. 
Data obtained in0.1 M Mops buffer (pH 7.0), see Refs. [124,146,148] fordetails. 
a Numbers of Fe(II) atoms/mol added. 
b Time of freezing after aerobic Fe(II) addition. 
Note: (1) that HuLF and HuHF variants oxidizing iron slowly (E107A and E27A) show no dimers; (2) that HuLF and HoSF (85% L) show relatively arge 
percentages of clusters (including large, magnetic clusters) compared with HuHF; (3) that Fe (lid dimer formation i HuHF shows co-operativity (e.g., 8 
Fe atoms out of 10 added in dimers at 1 min). 
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followed by migration of one or both atoms from the 
ferroxidase centre to the iron-storage cavity and to the 
3-fold channels. If only one Fe 3÷ left the ferroxidase 
centre and was replaced by Fe 2÷ then one-electron oxida- 
tion might follow. 
The O atoms of the core come from water and not from 
dioxygen, since when 180 2 was used as an oxidant, no 
evidence was found for the presence of the heavy isotope 
in the resulting iron core [178]. It is interesting to recall an 
earlier oxidation scheme [36] which was not dissimilar to 
that of Scheme (a) except hat 0 2 was bound between two 
Fe(II) on neighbouring subunits and both oxygen atoms 
were subsequently incorporated into the core. 
4.4. Fe(llI)-tyrosinate and tyrosine radicals 
Very recent work suggests that Fe(II) oxidation in 
ferritin is more complex than any of these mechanisms 
implies. When 0 2 was admitted to an anaerobic mixture of 
apo-BfHF and FeSO 4 (1 mM in subunits, 24 Fe/molecule 
[pH 7.0], 0.45 M C1-), or when FeSO4 was added to an 
aerobic solution of the apoferritin, a purple colour ap- 
peared, which was replaced within a few minutes by the 
amber colour characteristic of ferritin iron cores [ 169]. The 
purple species (absorbance maximum 550 nm) was identi- 
fied by Resonance Raman spectroscopy as a tyrosinate 
Fe(III) charge transfer complex [169]. A species absorbing 
in the same region appeared very rapidly when Fe(II) was 
added to apo-BfHF in a stopped-flow spectrometer under 
aerobic conditions [154]. It was estimated to account for 
about 20% of the Fe(II) oxidised. Aerobic addition of 
Fe(II) to HuHF (34 Fe/molecule, pH 7.0) also led to an 
increase in absorbance at550 nm. This absorbance r ached 
a maximum in under 0.5 s and then decayed over about 5 s 
(although not to zero) [148]. Under these conditions the 
absorbance was found to extend broadly over the range 
400-800 nm with a maximum at 650 nm [172] and the 
presence of Fe(IIl)-tyrosinate in HuHF has not yet been 
verified. Possibly another species (e.g., diferric-peroxo), or
more than one absorbing species, contributes to the wide 
band in HuHF [172]. Absorbance in the near UV (300-400 
nm) also increased in HuHF and continued to do so during 
the period in which the visible absorbance declined 
[ 148,172]. A kinetic study of the putative Fe(IIl)-tyrosinate 
in BfHF showed that after its initial rapid formation and 
decay, it was not completely regenerated by a second 
Fe(II) addition until after a lapse of 12 h [154]. In HuHF 
the initial coloured species is likely to have already de- 
cayed by the time (30 s) when the major species (the 
Fe(III) p~-oxo-bridged dimer) was observed by conven- 
tional MiSssbauer [96,124,148,163,172] and UV-difference 
[ 148,171 ] spectroscopy. The identity of the initial species 
and its mechanistic relationship to the Fe(III) dimers is 
uncertain, and remains a problem for research. The Fe(III) 
dimers fail to form in ferroxidase centre variants E27A and 
E107A of HuHF in which Fe(II) oxidation is very slow 
[148]. In the variants examined so far, the visible ab- 
sorbance also fails to appear in E27A, Y34F and Q141E 
(E107A not examined), showing that its formation depends 
on an intact ferroxidase centre [148,168]. However, its 
appearance seems not to be essential for dimer formation, 
for catalysis of Fe(II) oxidation, or for the subsequent s eps 
leading to mineralization, since, in both EcBFR (in which 
residue 141 is glutamate, not glutamine) and in HuHF 
variants Q141E and Y34F, and also in EcFTN, these 
processes occur without detection of the coloured species 
[148,124,172,174]. However, it is conceivable that in these 
ferritins the coloured species forms and decays within the 
dead time of the stopped-flow spectrometer. Tyr 34, a 
conserved residue at the ferroxidase centre, has been pro- 
posed as the tyrosinate Fe(III) ligand [148]. However, 
Waldo et al. [169] consider this is unlikely since it is 
present in L-ferritins, which do not give the Fe(III)- 
tyrosinate species. They proposed that the ligand is Tyr 29, 
a residue on the outer surface of the molecule [ 169], but no 
reduction in absorbance at550 nm is found in HuHF-Y29F 
(or in Y32F or Y137F) [172]. It is intriguing, nevertheless, 
that the blue species is not seen in several ferritins (includ- 
ing EcBFR and EcFTN) which do contain Tyr 34, but in 
which iron ligands or charge balance at the ferroxidase 
centre are altered [148,172,174]. Indeed a blue absorbance 
has been generated in an EcFTN variant E130A (E144A 
using H-chain numbering) see Figs. 6 and 8 [172]. 
Another interesting recent observation (by EPR spec- 
troscopy) is that of a tyrosine radical. This radical is 
associated with Fe(II) oxidation in HuHF, although it is 
seen only after oxidation is complete and decays within a 
few minutes [179]. Again Tyr 34 seems to be the residue 
concerned. However, only one tyrosine radical is observed 
per 300 Fe(II) atoms oxidised and its significance is 
unclear. A different EPR signal attributed to an amino acid 
radical but not to tyrosine or tryptophan is also seen in 
rapidly frozen samples within about 20 ms after addition 
of Fe(II) to horse spleen apoferritin [180]. Understanding 
the mechanism of Fe(II) oxidation in H-ferritin and the 
subsequent steps leading to mineralisation is one of the 
most challenging and exciting aspects of current research. 
4.5. The dinuclear Fe centres of ferritins and other pro- 
teins compared 
The dinuclear metal centres observed or proposed for 
the three ferritins described above (HuHF, EcFTN and 
EcBFR) which have been associated with catalytic Fe(II) 
oxidation are shown schematically in Fig. 8, where they 
are also compared with the di-iron centres of ribonu- 
cleotide reductase (RNR, R2 subunit) [181,182], methane 
monoxygenase (MMO) hydroxylase (subunit) [183] and 
haemerythrin [184]. The di-iron centres of these proteins 
are found, like those derived for the ferritins, at the centres 
of helical bundles. Based on the relative arrangements of
iron ligands with respect to their positions along the 
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helices the dinuclear iron proteins fall into the two classes: 
haemerthyrins in class I, RNR R2 and MMO and stearoyl- 
ACP desaturase in class 2 [177]. The similarities between 
the six centres are striking, especially between the dinu- 
clear centre of EcBFR and those proposed for the diferrous 
forms of ribonucleotide r ductase (based on the di-Mn(II) 
derivative [181,185]) and also stearoyl-ACP desaturase 
[177] and the acetate derivative of methane monoxygenase 
[182]. It is clear that the ferritins fall into the class 2 group. 
In EcBFR each Fe atom is ligated by one histidine residue 
and the two Fe atoms are bridged by two carboxy groups 
as in the di-Mn(II) (and presumably di-Fe(II)) form of R2. 
It may be speculated that the structure of the dinuclear 
centre shown for EcBFR corresponds to the diferrous form 
and that breakage of the Glu 127 bridge accompanies 
Fe(II) oxidation, as proposed for RNR R2 [181,175]. In 
R2, formation of the dinuclear Fe(III) centre is accompa- 
nied by the production of a stable tyrosine radical (Tyr 
122), Fig. 8, at about 5 ,~ from Fel and this radical is 
implicated as a source of reducing potential in the activity 
of the enzyme complex [182]. In HuHF, Tyr 34 lies at 
about 5 A from Fe2. This tyrosine is conserved in all 
known ferritin sequences, including those of L-subunits 
and it may have a structural rather than a functional role. 
An organic radical giving a g '= 2 EPR signal has been 
reported for EcBFR, but it has not been identified [98]. 
Another point of great interest is the non-identity of the 
dinuclear centres of the three ferritins in Fig. 8. EcFTN 
and HuHF contain only one histidine ligand (of Fel), but 
have glutamine instead of the second bridging glutamate 
(Glu 127) of EcBFR. Also, the glutamate ligands of Fe2 in 
EcFTN and HuHF, replacing His 130 in EcBFR, are at 
different sequence positions. Glu 130 of EcFTN corre- 
sponds to Ala 144 in HuHF, whereas Glu 49 (Glu 61 using 
H-chain numbering and a proposed ligand of Fe2 in HuHF) 
is a ligand of Fe3 (not shown in Fig. 8, see Fig. 6c and 
Table 1). Glu 130 is at an equivalent position to His 130 of 
EcBFR (in helix C) but Glu 49 (61), in helix B, is at a 
different position not only to those of His and Glu 130, but 
to the equivalent ligand of the other class 2 di-iron proteins 
(see Fig. 8). The significance of the differences in the three 
iron sites of these ferritins remains to be determined. Glu 
130 (or its sequence quivalent) is known only in the two 
bacterial non-haem ferritins (EcFTN and HpPFR) [63,66] 
(Table I). 
4.6. Role of  third iron site? 
Evidence has been summarised above implicating the 
dinuclear iron sites of Figs. 6 and 8 in the initial oxidative 
steps leading to iron storage in HuHF, EcFTN and EcBFR. 
In HuHF a third metal site has been observed on the inner 
surface of the protein shell [82]. Glu 61 and Glu 64 are the 
ligands binding Tb 3+ at this site, which was proposed to 
be a nucleation centre for the iron core. Movement of Glu 
61 (also a ligand of Fe2 in Fig. 8) was proposed to assist in 
the transfer of iron from site 2 to the putative nucleation 
centre. However, substitution of Glu 61 and Glu 64 by 
alanine produced no dramatic perturbation of core forma- 
tion or of Fe(II) oxidation [146]. Moreover the observed 
initial stoichiometry of 2Fe(II) oxidised per 02 suggests 
that only the dinuclear iron is involved in the first oxida- 
tive step [149,156,158-161,172]. 
The situation in EcFTN may be different. Here there are 
clearly three Fe3+-binding positions (Fig. 6c). The third 
site (ligands Glu 140 and 144 (H-chain numbers)) again 
o 
lies on the cavity surface (at 7-8 A from the dinuclear 
iron). However, its position and ligands are unique to 
EcFTN (residue 144 is Ala in HuHF). Moreover, the initial 
stoichiometry of about 3 Fe(II) oxidised/O 2 has been 
observed using an oxygen electrode (Treffry, Zhao, Quail, 
Guest and Harrison, unpublished work). Thus oxidation of 
the three Fe 2+ of Fig. 6c by a single dioxygen molecule is 
a possibility. It is particularly interesting to note that, in 
ribonucleotide reductase R2 subunit, three Fe 2+ may be 
oxidised by one dioxygen molecule during the formation 
of the diferric site, together with the nearby tyrosine 
radical and the 4-electron reduction of dioxygen. In this 
case, no third Fe binding site has been observed [ 186,187]. 
In EcBFR evidence for formation of a mononuclear i on 
site has been provided by observation of EPR signals 
(g = 2.04, 2.015, 2.00) attributed to Fe(NO) 2 (LeBrun, 
Andrews, Moore and Thomson, submitted). Neither the 
position of this iron in the protein shell nor its relationship 
to the dinuclear centre is known, but a site on the cavity 
surface is suggested. 
4.7. Why heteropolymers? - the role of  L-chains and the 
disadvantage of  too many H-chains 
Another intriguing structure-function problem is the 
role of L-chains of vertebrate ferritins that lack the intra- 
subunit ferroxidase centres of H-chains. Whereas horse 
spleen ferritin has a relatively high iron content (averaging 
2700 Fe atoms/molecule) and high average percentage 
L-chain (ca. 85%), the L-chain fraction extracted from it is 
devoid of iron [77]. In addition, recombinant human L- 
polymers bind less than 10 Fe atoms/molecule during 
expression in E. coli, whereas the H-homopolymer accu- 
mulates up to 200-300 Fe atoms/molecule under the 
same conditions [166]. Although ferritin molecules con- 
taining only L-chains do not seem to take up a significant 
amount of iron in vivo, the L-chain clearly has an impor- 
tant role in association with H-chains. In vitro studies of its 
functionality together with those of H-chain homopoly- 
mers, and reassembled H/L  copolymers, have provided 
vital information concerning the complementarity of the 
two types of ferritin chain. Recombinant human L-chain 
homopolymers are able to build iron-cores starting from 
Fe(II) at pH 7.0, although more slowly than human H-chain 
apoferritin and native horse spleen apoferritin (which has 
about 3 H-chains/molecule [93,96,146-148,150,151,156, 
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166,167,172]). It has been postulated [165] that L-chains 
possess an alternative Fe(II) oxidation site (probed by 
VO2+-binding) and that this could be a metal site with His 
136 and Asp 139 as ligands identified by X-ray crystallog- 
raphy and situated near the 3-fold channel on the cavity 
side [188]. However, in BfLF His 136 and Asp 139 are 
replaced by proline and serine respectively [36,189] and 
oxidation must occur elsewhere in this ferritin, probably at 
nucleation sites involving carboxy ligands [83]. Recent 
data show that the substitution of carboxyl groups lining 
the 3-fold channels or exposed on the cavity surface of 
HuHF do reduce the rate of core formation possibly due to 
interference with iron entry and nucleation respectively 
[190]. It has also been found that recombinant HuLF will 
accept Fe(III) produced by HuHF and use it for core 
formation [151]. In contrast, H ferritins are relatively poor 
core-formers [146,191,192]. It is also noted that iron-cores 
in recombinant L-ferritins and on native heteropolymers 
are slightly larger and more regular than those in H-chain 
ferritin as viewed by electron microscopy [150]. These 
experimental findings have led to the view that L-chains 
may be better at ferrihydrite nucleation [150,151 ]. A possi- 
ble explanation is that the cavity faces of L-chains have 
more carboxy ligands (or negative charges) than those of 
H-chains (Table 2). This explanation is supported by the 
finding, in HuLF, that the substitution by histidine of Glu 
57 and Glu 60 (residues exposed on the cavity surface) 
reduced the efficiency of core formation [ 190]. 
Although the H-chain is essential for rapid Fe(II) oxida- 
tion [37,147], too great a proportion of H-chains leads to 
protein aggregation i  vitro, probably due to Fe(III) loss 
and hydrolysis outside the molecule [191]. Iron newly 
oxidized in H-ferritin may also be lost to other molecules: 
in vitro it can be donated to transferrin [193] as well as to 
other ferritin molecules [192]. Production of H20 2 in 
Fe(II) oxidation catalysed by H-chains [159,171] could 
also lead to toxicity, if the peroxide is not disposed of, but 
the rapid provision of alternative oxidation sites on iron 
core particles avoids this problem. Thus it seems to be 
advantageous for ferritin molecules to contain both H- and 
L-chains. In recent experiments with H /L  heteropolymers 
reassembled in specific proportions, iron was incorporated 
optimally in molecules containing between 5 and 8 H- 
chains [194]. In M/Sssbauer experiments relatively high 
proportions of iron atoms are found in iron core clusters in 
native ferritins (horse spleen) [146] or in HuHF and HuLF 
mixtures [124] than in H-homopolymers (Table 3). Studies 
aimed at constructing a ferroxidase centre in the human 
L-chain showed that the presence of the metal ligand 
residues, especially Glu 62, strongly interfered with L-chain 
folding. However, when the variants were induced to fold 
by co-assembly with wild-type L-chains, they showed 
ferroxidase activity comparable to that of the H-chain 
[195]. 
As far as is known, plant ferritins are homopolymers of
a single subunit type and this also applies to bacterial 
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Fig. 9. Overproduction f EcFTN and EcBFR during the growth cycle of 
E. coli, U A650; • EcFTN; A EcBFR. Reproduced with permission 
from [123]. 
ferritins. Plant ferritins, so far sequenced, combine a pat- 
tern of carboxylate residues on their cavity surfaces like 
that of mammalian L-chains [99,151] with conserved fer- 
roxidase centre residues typical of H-chains (except hat in 
one of two known pea seed ferritin sequences residue 62 is 
histidine, not glutamate [37,53]). Recombinant pea seed 
ferritin (containing the seven ferroxidase centre residues) 
has recently been shown to exhibit ferroxidase activity 
[79]. EcFTN has all seven ferroxidase centre residues 
conserved (Fig. 6) and also catalyses Fe(II) oxidation 
[123,124] but, as indicated above, it displays some differ- 
ences in its iron centre (Figs. 6 and 8) and also shows a 
different distribution of cavity residues from those in either 
H- or L-chains of mammals (Table 2). In BFRs of E. coli 
[62,75], Fig. 8, and A. vinelandii [64], five of the putative 
ferroxidase centre residues are conserved. EcBFR is known 
to catalyse Fe(II) oxidation although at a slower rate than 
EcFTN or HuHF [37,75,123] and this catalysis is greatly 
impaired by substitution of each of three carboxylates 
(made one at a time) at the proposed ferroxidase centre 
[175]. It is not clear why two different ferritin molecules 
have evolved in E. coli, although it has been postulated 
that EcFTN, which remains at a constant level throughout 
bacterial growth, is responsible for iron homeostasis, 
whereas EcBFR, which is produced in maximal amount 
during stationary phase (Fig. 9) is more comparable to the 
L-ferritins of vertebrates [123,196]. However, in studies on 
bfr and fin single and on bfr, fin double mutants of E. 
coli, no physiological function was identified for EcBFR, 
whereas EcFTN was shown to play a role both in iron-stor- 
age and in the efficient utilisation of iron (Andrews, 
personal communication). 
4.8. The route of Fe(ll) entry into ferritin protein shells 
The most direct route (about 12 A) from the outside of 
the molecule to the ferroxidase centre appears to be a 
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small intra-subunit 'channel' in the H-chain [82]. In L- 
chains the ferroxidase centre is blocked by a salt bridge, 
and the channel by a leucine residue. It is not known 
whether Fe(II) uses the channel in H-chains. However, it is 
known that Fe(II) can reach the cavity of L-chain ferritin 
homopolymers. 
Various studies have implicated the 3-fold inter-subunit 
channels directly or indirectly in iron entry as discussed in 
Section 4.1. Several metal ions, (Cd 2+, Ca 2+, Zn 2+ and 
Tb 3+) have been shown by X-ray analysis to bind in the 
3-fold channels of both H- and L-homopolymers and 
native heteropolymers of ferritin [34,36,82] (see Fig. 4 for 
an example). Inhibition of iron incorporation by zinc or 
terbium indicated that these metals have common sites 
both in horse spleen ferritin [90,197], and in recombinant 
human H-chain ferritins [96], although this does not defi- 
nitely or exclusively implicate the channel sites. However, 
metal binding and competition studies (e.g., Ref. [90]) and 
use of horse spleen ferritin chemically modified in the 
outer regions of the 3-fold channels [92,94] show that these 
regions bind Fe(II). EPR spectroscopic measurements on
Fe 3+. NO complexes of recombinant human H-chain fer- 
ritin specifically pinpointed His 128, Cys 130 and probably 
His118 as iron ligands which are situated in the outer 
channels [198]. Again recombinants with residue substitu- 
tions in the narrowest parts of the channels (Aspl31 and 
Glu134 changed to alanine or histidine) incorporated iron 
more slowly than the wild type [96]. However, if the 
threefold channels are used for the passage of iron a 
specific mechanism for passing Fe(II) along them does not 
seem to be required in all ferritins, since channel residues 
are not highly conserved in bacterial and invertebrate 
ferritins (Table 1). Alternative routes may be available, 
such as the intra-subunit channel. 
4.9. Iron oxidation in the absence of dioxygen 
Although, in the presence of 02, ferritin can utilise its 
ferroxidase centres, under anaerobic conditions, Fe(II) 
added to apoferritin, or produced in situ by core reduction 
(see below), can also be oxidized either by ferricyanide or 
by oxidized cytochrome c, cytochrome c-551, cytochrome 
b5, metmyoglobin or plastocyanin giving apparently nor- 
mal cores [199,200]. These cores must form by Fe(III) 
hydrolysis without incorporation of atoms of molecular 
oxygen. Rates of haem reduction by reduced horse ferritin 
were found to be < 0.2 M 1 . s i for metmyoglobin, but 
1.1 × 10 2 M -1"  s -1  for horse ferri-cytochrome b5 and 
1.1 × 103 M i. s J for horse ferri cytochrome c [200]. 
These results imply that the redox mechanism in the 
absence of 02 involves long range electron transfer through 
the ferritin protein shell to iron within the cavity. Cy- 
tochromes, which are located in the mitrochrondia, are 
unlikely to be potential physiological redox partners for 
ferritin, however. An alternative to long range electron 
transfer from an external donor apparently resides in the 
protein shell itself. Microcoulometric titrations of 
(oxidised) horse spleen apoferritin performed by Watt and 
colleagues indicated that the protein can acquire up to six 
electrons [201,202]. These authors concluded that the pro- 
tein shell itself must contain redox centres. When ferri- 
cyamide was added anaerobically to the protein these 
centres were apparently re-oxidised, since Fe(II) added to 
the treated protein was converted to Fe(III) (as measured 
by EPR spectroscopy). It is uncertain whether the redox 
properties are intrinsic to the protein shell or whether they 
reside in a 'cofactor' or redox active substance attached to 
the protein, but the numbers suggest he possibility that 
they could be associated either with H-chains or with the 
3-fold or 4-fold inter-subunit nterfaces. Watt et al. [202] 
suggest the involvement of tyrosine residues near the 
4-fold interfaces. Anaerobic oxidation by nitric oxide of 
protein bound Fe(II) has been observed in both mam- 
malian ferritin [198] and EcBFR ([170] and LeBrun, An- 
drews, Moore, Thomson, submitted). The physiological 
significance, if any, of this observation eeds to be as- 
sessed. 
4.10. The effect of phosphate on iron-core formation 
Native ferritin iron-cores usually contain some inor- 
ganic phosphate [99,108-112] but most in vitro iron-load- 
ing experiments have been carried out with iron alone. 
When phosphate is added with iron, smaller, less regular 
cores are formed [121,123,125]. About 60% of the phos- 
phate present in horse spleen ferritin is released in the 
initial stages of iron release and is probably superficial 
[203,204]. Ferritin iron-cores reconstituted without phos- 
phate will absorb this and other anions [203]. Such experi- 
ments, together with the relatively low intracellular con- 
centration of iron compared to phosphate, point to some 
degree of compartmentalisation of these components in 
animal cells. The higher P:Fe ratios and the disorder 
observed by electron diffraction and EXAFS in iron-cores 
of plant [99] and bacterial ferritins [120,123] may reflect 
higher phosphate concentrations in the media from which 
these ferritin acquire their iron, e.g., 12 mM in plastids 
[99]. The amount of phosphate in these ferritins is, indeed, 
so high (e.g., 640 P/molecule in pea seed ferritin [99]) 
that they may be considered to be stores of phosphorus as 
well as of iron. 
Recent experiments on the kinetics of Fe(II) oxidation 
by horse spleen apoferritin in the presence of phosphate 
(12 Fe(lI) added per apoferritin molecule with equimolar 
phosphate [205]) have shown two effects. The rate at 
which Fe(II) is oxidised, measured by MiSssbauer spec- 
troscopy, is significantly increased in the presence of 
phosphate and the rate of loss of monomer Fe(III) (g' = 4.3 
EPR signal) due to the formation of EPR-silent core is also 
accelerated. The 2-fold acceleration of Fe(II) loss is inter- 
preted as an effect of anion binding on the redox potential 
of the ferroxidase centre (making it more negative), al- 
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though an alternative xplanation may be that fewer fer- 
roxidase centres are occupied by Fe(III) owing to the 
greater affinity of the phosphate-containing iron-core. 
There is no evidence that phosphate binds to apoferritin in 
the absence of iron. At variance with this result was the 
finding of no acceleration by phosphate on rates of Fe(II) 
oxidation measured as 0 2 consumption [149]. The effect of 
phosphate on the anaerobic binding of Fe(II) has also been 
investigated [206,207]. The presence of phosphate markedly 
increased Fe(II) binding, but only 8 Fe(II) per molecule 
were retained after gel filtration of either horse spleen 
apoferritin or ferritin containing a phosphate-free reconsti- 
tuted core. The iron was assumed to be bound in the 3-fold 
channels and this result was taken as evidence against he 
hypothesis that (in the absence of phosphate) Fe(II) is 
bound and oxidised at iron core surfaces in the second 
stage of ferritin formation. However, this conclusion is not 
necessarily correct since the Fe(II) atoms need only to be 
bound transiently before oxidation. Apo-AvBFR binds 
more Fe(II) than horse spleen apoferritin, namely 25 
Fe(II)/molecule at pH 5.5 and 150 at pH 9.0, with proton 
release increasing to up to 2 per Fe(II) at the higher pH 
[206]. The larger number of Fe(II) atoms bound by holo- 
BFR than by HoSF is attributed to its greater phosphate 
content [206]. The effect of phosphate on iron loading in 
EcBFR has recently been investigated [170]. Aerobic dial- 
ysis with phosphate l ads to the loss of EPR signals due to 
non-haem iron, probably due to the shepherding by phos- 
phate of iron from the ferroxidase centre into the cavity 
with the formation of a ferric phosphate core. Anaerobic 
dialysis leads to Fe(III) reduction and the transfer of Fe(ll) 
from the core to the non-haem sites on the protein. 
4.11. Can ferritin store iron as Fe(ll) ? 
Given the low redox potentials of ferritin ( -  190 mV at 
pH 7) and BFR ( -420  mV) iron cores and given the 
intracellular presence of a variety of molecules that may 
act as oxidants, it seems probable that ferritin iron is 
normally Fe(III). However, it has been proposed that under 
oxygen limitation ferritin can retain or store iron in the 
reduced state [110,120,208,209]. If ferritin or BFR iron- 
cores are reduced stoichiometrically in the absence of 
chelators in vitro, most of the Fe(II) is retained by the 
protein shell during anaerobic gel filtration [110,120]. Ad- 
dition of chelators causes this Fe(II) to be released. In 
other experiments, 20 mM Fe(II) was added to apoferritin 
(480 Fe(II)/molecule, pH 7.0) in air and it was shown by 
EXAFS that Fe(II) oxidation took several hours to com- 
plete [208]. The Fe(II) was judged to be inside the protein 
shell because of its failure to react with o-phenanthroline. 
It is difficult to assess the validity of this conclusion, 
however, because Fe(II) seems to be readily released to 
chelators in other experiments [ 110,120,199,210]. The frac- 
tions retained may have been oxidised to Fe(III). In other 
work, significant binding and retention of Fe(lI) atoms has 
been found under anaerobic onditions only if a phos- 
phate-containing core was present or if Fe(II) and phos- 
phate were added together [207]. However, recently a 
'magneto-ferritin' has been produced under controlled re- 
constitution conditions (including slow oxidation) [211], 
This ferritin is black and contains magnetite-maghemite 
(Fe304-',/Fe203) [212]. It is presently unknown whether 
any iron is stored as Fe(II) in vivo since ferritin has always 
been isolated in the presence of air. In this connection, it is 
interesting that a ferritin (of low iron content) has been 
isolated from an obligate anaerobe, Bacteroides fragilis 
[72]. One hypothesis i  that in the absence of superoxide 
dismutase or catalase, this ferritin's function is to protect 
against free radical damage in the event of sudden expo- 
sure to oxygen, rather than to act as a store of Fe(II) under 
anaerobiosis [72]. 
4.12. Can ferritin bind Fe(lll)? The transfer of Fe(III) 
between ferritin molecules 
An iron storage mechanism based on Fe(II) oxidation 
may have evolved in ferritin because of the extremely 
limited solubility of Fe(III). Although, in principle, Fe(III) 
could be delivered as its soluble complex with a small 
chelate molecule, e.g., citrate or ATP, problems could 
arise with respect o the traversal of the ferritin shell by 
such a complex, and to the competition between protein 
ligands and chelate molecules for the Fe(III). In in vitro 
experiments only limited amounts of 59Fe(III), presented 
as its citrate complex, were bound to ferritin cores and 
none to the protein shell [213]. Significant uptake occurred 
only in the presence of ascorbate [141]. However, it is 
noteworthy that iron oxidised by one ferritin molecule can 
be transferred to another, where it is bound by the iron-core 
[151,124,192]. Two types of experiment have indicated 
such transfer: (1) 57Fe(III), mainly or entirely in the form 
of monomeric species, has been found by M~ssbauer 
spectroscopy to move to molecules containing M~Sssbauer 
silent 56Fe cores [124,192]. (2) Ferritin molecules, that, on 
their own, are unable to oxidise Fe(II) and develop iron 
cores at pH 5.5 (L-chain ferritin or HuHF with altered 
ferroxidase centres), are enabled to incorporate iron by the 
presence of molecules with fully active ferroxidase centres 
[124]. These findings are consistent with the observation 
that part of the iron newly oxidised by ferritin can be 
donated to iron binding macromolecules like transferrin 
[147,193]. How the iron is released from the ferroxidase 
centre is unknown, but there is evidence that, in addition to 
movement into the cavity, some of the oxidised iron can 
transfer to the 3-fold channels, where it is observed as a 
mononuclear species [148]. The iron probably moves from 
the channels of the donating species to those of the accep- 
tor ferritin or into its own cavity and the direction of 
movement is determined by the relative capacities of the 
ferritins to mineralise. It is unclear whether transfer e- 
quires the close association of donor and acceptor. The 
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possibility that ferritin can act as an Fe(III) donor in vivo 
is intriguing, particularly if it can donate its iron to other 
(non-ferritin) molecules. Perhaps of more relevance is the 
evidence that ferritin can take up Fe(III) if presented in a 
suitable form. 
A number of in vitro experiments have been reported, 
which have led to the conclusion that caeruloplasmin, 
acting as a ferroxidase, can act as a source of Fe(III) for 
storage within ferritin [214-216]. This conclusion was 
based on the assumption that any increase in absorption at 
310 or 380 nm in apoferritin- caeruloplasmin-Fe(II)-O 2 
mixtures was due to ferritin core formation. However, 
more recent work has shown that, far from increasing iron 
incorporation i to ferritin, caeruloplasmin competes with it 
for iron, with which it forms soluble Fe(III) polymer 
complexes [217]. The proposal [218] that iron oxidised by 
xanthine oxidase can be incorporated into ferritin should 
now be re-examined. 
4.13. Model complexes for ferritin iron-cores 
Several synthetic oligomeric iron-oxo complexes have 
been produced which contain two, three, four, six, eight, 
eleven Fe(III) [219-221 ] or sixteen Fe atoms together with 
a single Co or Mn [222]. The Fe(III) atoms are linked by 
oxo or hydroxo bridges with carboxylate or phenolate 
ligands attached to the outermost irons of the cluster. 
Analysis of these complexes (e.g., MSssbauer parameters 
and magnetic properties as a function of size) may provide 
insights into ferritin core formation. One of the more 
interesting of the synthetic analogues, particularly in rela- 
tion to the magnetoferritin [211,212] referred to above, is a 
mixed valence polymer produced under low oxygen con- 
centration containing 4 Fe(III) and 8 Fe(II) atoms at 
interstitial positions of a cubic close packed oxygen lattice 
[223]. Most of these complexes have been formed in 
non-aqueous olutions. However, controlled polymerisa- 
tion in aqueous media has given defined, water-soluble 
complexes which contain 17 or 19 Fe(III) [221,224], as 
shown in Fig. 10. 
5. Haemosiderin 
Normal cells store iron mainly in ferritin molecules, but 
under conditions of iron excess some of it is shunted into 
another storage form known as haemosiderin [225]. The 
name 'haemosiderin' reflected its presumed origin, but its 
iron is non-haem. Under the electron microscope 
haemosiderin s recognised as irregular, massive clusters of 
electron-dense particles, most of which are membrane-en- 
closed [226]. These are thought o be iron-laden secondary 
lysosomes and have been named 'siderosomes' [227]. 
Clusters, visible under the light microscope, are typical of 
iron-loaded tissues, including liver, spleen, bone marrow, 
brain, heart and many other tissues, including some which 
e14 
O34 
Fig. l f). Structure of water-soluble Fe(III) polymer containing 19 Fe(III) 
atoms. In this hydroxo(oxo) iron cluster the close-packed cluster core is 
enclosed in a shell of "heidi' ligands (heidi = N(CH2COOH) 2 
(CH2CH2OH), which are complexed to further iron atoms. The cluster 
core unit is [Fev(~3-OH)6(p.z-OH) 4 {l.z3-O) Fe}2] I~+ and this is sur- 
rounded by ten iron heidi units linked to the core by p.~-O, tx2-OH and 
alkoxo bridge units from the heidi ligands. The formula of the whole 
complex is: [Fel9 (~3-O)6 (I~-OH) 6 (p~2-OH)~ (heidi)10 (H20)12] +, 
Diagram by courtesy of A.K. Powell. 
are malignant [225-227]. Haemosiderin is typically insolu- 
ble, as isolated, in contrast o the soluble ferritin, but it can 
be solubilized by treatment with alkali and detergents 
[228]. Ultrastructural immuno-gold staining showed that 
siderosome granules are recognised by anti-ferritin anti- 
bodies, but their immunoreactivity is significantly lower 
than that of the cytosolic ferritin [229]. These data support 
the hypothesis that haemosiderin is a degradation product 
of ferritin [225,227]. This has been confirmed for phy- 
tosiderin, an insoluble iron-containing product isolated 
from pea seed, which was found to contain a peptide 
derived by radical mediated cleavage of 20 N-terminal 
residues from the ferritin subunit [230]. Siderosomes iso- 
lated from iron-overloaded rats were found to contain an 
electrophoretically fast (F) type of ferritin containing a 
subunit of 17.3 kDa, as opposed to the cytosolic ferritin 
subunit of 20.7 kDa [231]. The shorter subunit was shown 
to originate by the specific cleavage of a 19 amino acid 
C-terminal peptide from the L-subunit [232]. Electron 
diffraction and MtJssbauer analyses howed that sideroso- 
mal ferritin and haemosiderin iron cores are similar and 
have ferrihydrite structures. Their particle sizes are smaller 
than those of cytosolic ferritin cores [111]. These findings 
indicated that ferritin is taken up by lysosomes, and that 
subsequent processing involved a partial dissolution of the 
core, and degradation to siderosomal ferritin and to the 
insoluble haemosiderin. The enzymes causing the cleavage 
have not been identified, but earlier studies indicated that 
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cathepsin D is probably not involved, although this prote- 
olytic enzyme is highly represented in siderosomes [227]. 
It is not unlikely that a partial reductive dissolution of the 
iron core catalyses production of free radicals, which 
damage the protein and facilitate its proteolytic attack 
[233]. The haemosiderins from various iron-loaded animals 
were consistently found to have ferrihydrite-like iron cores 
similar to those of ferritin [234], but unexpected and 
important differences were observed in haemosiderins from 
some pathological tissues. The livers of patients with 
primary (genetic) haemochromatosis treated by venesec- 
tion were found to contain haemosiderin with amorphous 
ferric oxide cores [127,235], while spleens and livers of 
patients with secondary iron overload (due to treatment of 
thalassemia by repeated blood transfusion) contained a 
haemosiderin with crystalline goethite-like iron 'cores', 
and this was unrelated to treatment by chelation therapy 
[127,236,237]. These differences were indicated by 
MiAssbauer spectroscopy, [236], EXAFS [127] and electron 
diffraction [235], and were found only in haemosiderins 
and not ferritins, which invariably had ferrihydrite cores. 
The haemosiderin from primary haemochromatosis was 
found to contain a major peptide of 20 kDa, and to release 
iron to oxalate 3-fold faster than that from secondary iron 
overload, which contained a major peptide of 15 kDa 
[238]. Recently, it was found that prolonged centrifugation 
in potassium iodide precipitated a non-ferritin, non- 
haemosiderin fraction which was termed pre-haemosiderin. 
It contained peptides of 17 and 21 kDa, the origins of 
which are unknown, and the structure of its iron cores 
resembled that of the corresponding haemosiderin: 
goethite-like in secondary haemochromatosis and ferrihy- 
drite in the other conditions [237]. These findings imply 
that there are multiple mechanisms of haemosiderin forma- 
tion, and that the intrinsic toxicity of haemosiderin iron 
may vary with its origin. The structural differences be- 
tween haemosiderin and ferritin iron cores in the two types 
of iron overload could not be accounted for by a simple 
conversion of crystal structure, and, in these pathologies, 
ferritin may not be an immediate precursor of haemosiderin. 
It has been postulated that, in secondary haemochromato- 
sis, ferritin iron may be partially solubilized in the lyso- 
somes and then allowed to reprecipitate to form the more 
stable, and less toxic goethite-like structure [112]. In pri- 
mary haemochromatosis, fast iron incorporation might in- 
duce a fast intracellular i on precipitation (possibly outside 
ferritin) with the formation of poorly-ordered cores [111]. 
6. Ferr i t in  as a source  of  i ron 
Mobilization of storage iron may occur under a variety 
of circumstances. In the embryonic red cell iron deposited 
in ferritin is rapidly utilized for haemoglobin production 
[239]. Blood loss, e.g., phlebotomy used in the treatment 
of iron-overload in humans [240], causes iron to be drawn 
from storage sites in the liver and spleen and used for 
haemoglobin synthesis in new red cells in the erythroid 
marrow. Experimentally, storage iron can be mobilized in 
perfused liver [241] or cultured rat hepatocytes [242] by 
the action of chelators, e.g., desferrioxamine, which are 
also administered in humans for removal of excessive iron 
stores. Iron can also be removed from both ferritin and 
haemosiderin in vitro [111,243]. Theil [36] has drawn 
attention to differences in the physiological roles of stor- 
age iron in different cell types. Probably all cells utilize 
iron stores for 'housekeeping' purposes, i.e., to enable 
synthesis of cytochromes and iron-containing enzymes 
within the same cell, while certain cells (hepatocytes, 
embryonic red cells and macrophages) tore iron for use 
by other cells, e.g., in the recycling of iron by senescent 
red cells, iron is temporarily stored in the reticuloendo- 
thelial cells of spleen and liver. Release mechanisms could 
be related to different demands for iron within different 
cell types. Although it is usually assumed that iron can be 
made available from intact ferritin molecules, it must also 
be reutilised from degraded molecules, since large iron-core 
deposits do not normally build up. In vitro, the relative 
availability of haemosiderin and ferritin iron depends in 
the origin of the haemosiderin deposits: in general, iron is 
less easily mobilised from ferritin than from the 
haemosiderin of primary overload, but more easily mo- 
bilised from ferritin than from the crystalline goethite 
deposits of secondary iron overload [111,243]. 
6.1. In vitro studies of iron release from ferritin and 
bacterioferritin and their biological relevance 
Ferritin and haemosiderin iron can readily be released 
by small reductants, assisted by Fe(II) chelators uch as 
2,2'-bipyridine [120,244], bathophenanthroline sulphonate 
[245] or ferrozine [148,246]. Reductants commonly used in 
the preparation of apoferritin include dithionite [120,244] 
and thioglycollate [201,247], and a variety of 'physio- 
logical' reducing agents have also found to be effective or 
partially effective in iron release, e.g., reduced flavins 
[248,249], superoxide [245,250,251], dihydrolipoate and 
related sulfydryls [252] and ascorbate or the mono-dehy- 
droascorbate radical [253]. None of these is clearly impli- 
cated in mobilisation of ferritin iron in vivo, however. 
Cellular concentrations of flavins are very low, but it has 
been proposed that an NAD(P)H-dependent ferrireductase 
promotes the mobilization of ferritin iron by means of a 
reduced flavin shuttle [254]. This enzyme, which has been 
partially purified, will reductively release iron from trans- 
ferrin and lactoferrin [254]. Ferritin iron can also be re- 
moved by photoreduction [255]. Ferritin iron has been 
reported to be mobilised by nitric oxide [256], but this has 
been reinvestigated and no significant release by NO gen- 
erated from 5-nitrosothiols was found in the absence of a 
strong Fe(II) chelating agent [257] which may have per- 
turbed the earlier results [256]. 
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In the crystalline °state pores through the apoferritin 
shell are only a few A wide. Nevertheless dynamic struc- 
tural fluctuations may allow some of the small reductants 
to enter the protein shell fast enough to interact directly 
with the core and remove its surface iron [249]. That this is 
possible is suggested by the finding that protoporphyrin IX 
binds at the inner surface of the horse spleen apoferritin 
shell, although a very long incubation period was allowed 
before crystallisation for structure determination [104]. An 
Fe(II) chelator (which may be the reductant itself) will 
help Fe(II) to find its way out of the molecule. Small 
Fe(III) chelators which mobilize Fe(III) from ferritin over 
hours or days (e.g., hydroxypyridinones) may also enter 
the molecule and leave bearing iron as the Fe(III)-chelate 
complex [258]. Low angle neutron scattering and NMR 
studies of horse spleen ferritin show that molecules of 
comparable size, e.g., sucrose and maltose, reach the cav- 
ity within a few seconds [259,260]. A recent kinetic and 
spectroscopic nvestigation of iron release to four chelators 
indicates that they can acquire iron from the dinuclear sites 
within the shell, possibly, by formation of ternary com- 
plexes [261]. However, rates of release measured with a 
series of organic reductants correlate better with redox 
potential than with molecular size, an observation inter- 
preted to imply that they do not penetrate the shell at a 
significant rate [262,263]. In the presence of ferrozine, a 
chelator with much higher affinity for Fe(II) than for 
Fe(III), reductants with redox potential higher than that of 
the ferritin core are able to release ferritin iron [263]. 
Dihydroflavodoxin, a protein of M r about 30000 is also 
capable of reducing core iron in both horse spleen ferritin 
and AvBFR under anaerobic onditions [199]. This proba- 
bly results from long range tunnelling of electrons medi- 
ated by aromatic groups within the protein [199]. Such 
long-range effects are potentially of great importance, 
since they obviate the necessity for small molecule reduc- 
tants under physiological conditions. 
A speculative scheme for in vivo ferritin iron mobiliza- 
tion [263] is shown in Fig. l l. In this model, iron is 
normally in the Fe(III) state, but when reduced, it remains 
within the protein unless removed by an Fe(II) acceptor. A 
FRR~ + H ÷ / , r / IDM 
Z F -Fe3÷~- -  FeZ+-IDM + 02 
F 
FRox  F -Fe2*~ Fe2._IAM 
IAM 
Fig. 11. Speculative scheme for physiological iron uptake and release by 
ferritin. Iron enters ferritin (F) as Fe 2+ and is oxidised in the protein by 
02 . The Fe 2+ is acquired from an iron donor molecule (IDM). A 
ferrireductase (FR) is required to release iron as Fe 3÷, which becomes 
attached to an iron acceptor molecule (IAM). Reproduced from [263] with 
permission. 
low molecular weight (5600 Da) protein has been identi- 
fied in human reticulocytes which seems to participate in 
the intracellular transport of iron for haem synthesis [264] 
and this has been suggested as a possible acceptor for 
ferritin iron [263]. The scheme is attractive because it 
proposes different mechanisms for iron uptake and iron 
release (this also applies to release after degradation within 
lysosomes). Since ferritin itself can act as a ferroxidase 
during iron uptake, no external oxidase is needed provided 
02 is available. 
Electrochemical titrations of horse spleen ferritin and 
AvBFR show that the iron core is more difficult to reduce 
in the latter (e.g., at pH 7, E~/2 = -420  mV for BFR 
compared with -190  mV for horse spleen ferritin 
[110,120,107]). This can be attributed to the phosphate-rich 
composition of the cores in native BFR, since reconstitu- 
tion in the absence of phosphate yields cores which exhibit 
a more positive potential [204]. The presence of iron core 
also influences the reduction of the haem in BFR. Spectro- 
electrochemical measurements show that the haem reduc- 
tion potential becomes more negative by about 250 mV in 
the presence of core ( -475  mV for holo- and -225  mV 
for apo-BFR, where holo- and apo- refer to the core) 
[108,248]. The question arises, does the presence of haem 
affect the reductive release of iron from the core? Al- 
though the measured potentials uggest hat haem is more 
difficult to reduce in BFR than the core, nevertheless Watt 
et al. [239] propose that reduction of the latter is mediated 
by haem. They found that, although neither core nor haem 
reduction potentials how pH dependence when measured 
in the pH range 7 to 9, holo BFR takes up 1.8_+0.2 
protons per iron atom reduced [107] (a value similar to that 
for horse spleen ferritin, which shows reduction potentials 
varying from -190  mV at pH 7 to -416  mV at pH 9 
[120]). This result could be explained if the electrons are 
taken up first by haem, and are then passed irreversibly to 
the core at higher potential [106]. The binding of haem to 
horse spleen ferritin was also found to accelerate iron 
release from the core [106]. The interaction between haem 
and core is consistent with the location of the latter 
between subunits on the inside surface of the protein shell 
as shown for EcBFR [85]. 
6.2. Ferritin as a donor of  iron to hepatocytes: its involve- 
ment in their cycling of  red cell iron 
When 59Fe-labelled rat liver ferritin was injected into a 
rat much of the label appeared in liver parenchymal cells 
[129,130]. Rat hepatocytes contain specific ferritin recep- 
tors [265,266] and a scavenger function is suggested [266]. 
Studies of the binding of radio-labelled rat liver ferritin to 
primary cultures of rat hepatocytes gave 4 × l0 4 binding 
sites per cell with an affinity constant of 1 × 10 9 M I at 
4°C [267]. At 37°C maximal uptake from these sites was 
1.3 × 105 ferritin molecules/cell per hour. This corre- 
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sponds to 5 X 10 6 Fe atoms/cel l /min for ferritin 
molecules bearing 2400 Fe atoms. Some further iron could 
have been taken up by binding of ferritin at low affinity 
sites. Ascorbate enhanced the cellular uptake of ferritin 
iron and apotransferrin hibited it [268]. The finding that 
chloroquine, which is thought o impair receptor recycling, 
depressed both ferritin and iron uptake suggests that recep- 
tor-bound ferritin is delivered to the lysosomes for degra- 
dation and iron release [268]. The iron from phagocytosed 
erythrocytes is converted into and released as ferritin. 
When rat Kupffer cells were cultured with hepatocytes, the 
released ferritin was taken up by the hepatocytes [23], 
where it then seemed to be processed by degradation 
within the iysosomes and some of its iron was released to 
the bepatocyte cytosol ferritin and also incorporated into 
mitochondria. 
The hepatocyte receptor has been isolated from humans 
[269], rat [265] and pig [270]. Its major component is a 
protein of M r 53 000. Consistent with its proposed scav- 
enger function the receptor was found to have a broad 
specificity both with respect o H- and L-subunit composi- 
tion and even across species [271]. 
Although this degradative pathway for release of iron 
from ferritin derived from other cells seems quite well 
established, and although cytosolic ferritin from the same 
cell can also be taken up and degraded [132], it cannot be 
ruled out that ferritin iron can also be made available from 
intact molecules in vivo. 
7. Regulation of iron storage 
7.1. Ferritin biosynthesis 
Ferritins from bacteria, plants and animals show a 
remarkable conservation i structural features and they all 
interact and incorporate iron in vitro in similar ways [37]. 
However, their expression is regulated with strikingly dif- 
ferent mechanisms in the three kingdoms, probably as a 
consequence of major differences in iron handling. 
The two types of iron storage protein found in bacteria 
(the heme containing BFR, found in E. coli, A. vinelandii 
and P. aeruginosa [75], and the non-heme FI'N found in 
E. coli, B. fragilis and H. pylori [63,66,72]), do not 
co-assemble to form heteropolymers [123]. The isolated 
ferritins and bacterioferritins appear to contain relatively 
low amounts of iron, a few hundred atoms per molecule, 
compared with an average of 1000 to 3000 atoms found in 
ferritin isolated from human liver or horse spleen. In 
particular the ferritin from the anaerobe B. fragilis was 
found to be essentially iron-free [72]. In E. coli the two 
proteins are regulated independently: the BFR content 
increases in the stationary phase of growth, while FTN 
remains constant hroughout he growth cycle [72]. The 
study of the mechanism of the regulation of their expres- 
sion may give important insights into their functional roles. 
Induction by iron has been found for the BFRs of 
Rhodobacter sphaeroides [272] and E. coli (Grogan, 
Thackray, Andrews and Guest, unpublished work) but not 
for that in Synechosystis [71]. In E. coli, iron induction of 
bfr expression is dependent on the ferric uptake regulator 
protein (Fur), although not on direct interaction of Fur with 
the bfr gene (Grogan et al., unpublished work). 
Plant and animal ferritins differ in the cytological local- 
ization and the control of their synthesis in response to 
iron. Plant ferritins are found in chloroplasts and plastids 
[49]. In soybean, ferritin subunits are synthesised as 32 
kDa precursors with an N-terminal transit peptide. The 
subunits are taken up by chloroplasts and processed to give 
the 28 kDa subunit found in the isolated protein [54,78]. 
An additional 26 kDa subunit has been found, but it 
originates from processing of the 28 kDa peptide [230]. 
The purified ferritins appear to be composed of a single 
type of subunit, although in some species (e.g., cowpea 
and maize) more than one functional gene has been identi- 
fied [273]. Ferritin expression is regulated by development 
and by iron, and the latter has been studied in detail. Iron 
salts increase plant ferritin protein up to 60-fold, with a 
parallel increase in ferritin mRNA [56,78]. Iron acts only 
at a transcriptional level, with no evident effect on transla- 
tion. Some light on the mechanisms of iron-induced fer- 
ritin expression came with the observation that iron in- 
duces the accumulation of abscisic acid, and that abscisic 
acid itself stimulates ferritin synthesis, albeit not at the 
same levels as does iron [274]. Thus abscisic acid and iron 
pathways are linked but probably not identical. Indeed it 
has been found recently that in maize only one of the two 
transcripts (FM2) accumulates in response to abscisic acid 
and, although both ferritin mRNA subclasses FM1 and 
FM2 respond to iron, FMI accumulates before FM2 [275]. 
In de-rooted plantlets abscisic acid is not involved in the 
induction of ferritin synthesis due to iron overload [276]. 
Hydrogen peroxide treatment was found to induce an 
accumulation of ferritin mRNA at low iron concentrations 
and it was concluded that in plants ferritin plays an 
important role in the response to oxidative stress [276]. 
Thus ferritin may have more complex functions in plants 
than the simple storage of iron. 
In animal cells, ferritin is invariably found in the cell 
sap and in lysosomes. Trace amounts of ferritins are also 
found in serum and body fluids of human and other 
mammals, but in some invertebrates, particularly insects 
and molluscs, the secreted ferritins are present in much 
larger proportion. An electron microscopic analysis of the 
larvae of the insect Calpodes ethlius showed more ferritin 
in the vascular system than in the cell sap [48]. Iron 
induced the synthesis of this ferritin also by increasing 
mRNA levels, and when the transcripts were added to a 
cell-free translation system, the encoded subunits were 
taken up and processed by dog pancreatic microsomes, a 
demonstration of the secretory nature of this type of 
ferritin [45]. The fresh water snail Lymnaea stagnalis 
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contains two types of ferritin, an intracellular form in the 
soma, and a secretory form in the yolk [38,277]. The yolk 
ferritin is secreted by the mid-gut gland and released in the 
blood lymph to be taken by the tissues. This secretory 
ferritin seems to act as a source of tissue iron. Recent 
cloning and sequencing of both types of L. stagnalis 
ferritin showed that the yolk ferritin has a canonical 18 
amino acid leader sequence for protein export. Yolk fer- 
ritin expression is under developmental control, while the 
soma ferritin is regulated by iron at the translational level 
[33]. In rat liver a significant proportion of H- and L-chain 
mRNA is associated with membrane bound po[ysomes and 
it increases during experimental inflammation [278,279]. 
An accurate in vitro study indicated that these mRNAs are 
translated, but are not taken up and processed by dog 
pancreatic microsomes, indicating that they do not encode 
for the secreted and glycosylated form of ferritin, the 
origin of which remains uncertain [280]. Probably the 
distinctive feature of vertebrate ferritin is the presence of 
L-chains (the only ferritin subunits without ferroxidase 
activity) which normally associate with the H-chains to 
produce heteropolymers with the ability to catalyse Fe(II) 
oxidation. 
7.2. Iron induction of ferritin synthesis in animals 
Induction of ferritin synthesis in response to iron admin- 
istration has been well documented in rats [129,131-]33] 
and in cell cultures [281-283], since it was first observed 
by Granick as an increase in ferritin in the gastrointestinal 
mucosa of guinea pigs after iron feeding [284]. The re- 
sponse to iron is rapid, e.g., in rats there was a maximal 
increase in synthesis of labelled ferritin at 6 h after an 
intraperitoneal injection of iron [129], and this may reflect 
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P.M. Harrison, P. Arosio / Biochimica et Biophysica Acta 1275 (1996) 161-203 187 
the need to provide an adequate means of iron disposal 
while at the same time avoiding cell damage. The injected 
iron is taken up into both pre-existing and newly synthe- 
sized molecules [129-133]. 
The mechanisms by which iron regulates ferritin bio- 
synthesis have been intensively studied. The major control 
mechanism is largely post-transcriptional although a minor 
increase in ferritin mRNA has also frequently been ob- 
served [285-287]. Iron administration to rats induced a 
2-fold increase in L-chain mRNA, leaving H-chain mRNA 
unaffected, the result of a specific transcriptional ctivation 
of the L-gene [287]. Similar findings have been reported 
for iron-loaded patients [288]. Long-term iron overload 
seems to up-regulate L-chain translation [289]. Both mech- 
anisms explain the selective up-regulation of L-chain in 
iron overload. The relative increase of L-chain mRNA may 
be peculiar to the liver, since various cultured cells, includ- 
ing HeLa cells [290], human myoblasts [291], activated 
T-cells, monocytes [292] and human hepatocytes [293] 
respond to iron with a 2-to 5-fold increase of both H- and 
L-chain mRNAs. Also cells from Xenopus leavis respond 
to iron and cadmium with a 5-fold increase of ferritin 
mRNA transcription [294]. A recent study showed that the 
iron-induced transcriptional up-regulation of H-chain mR- 
NAs varies greatly in different cell lines [295]. Significant 
differences were observed also between different erythroid 
cell lines: in human K562 cells the heme iron-induced 
increase of ferritin mRNAs was ascribed to stabilization of 
the transcripts [296], while in the mouse Friend erythro- 
leukemia cells, heme and protoporphyrin IX similarly, and 
selectively, up-regulated H-chain transcription [297]. The 
stimulatory effect was attributed to the H-chain promoter. 
7.3. Translational regulation of ferritin by iron 
A cytoplasmic translational control mechanism was 
suggested by the observation that rats, which had received 
injections of actinomycin D or cordycepin prior to ferric 
ammonium citrate, gave the same two-fold increase in the 
amount of ferritin mRNA in liver polyribosomal fractions 
as rats receiving iron only [298]. The increase in 
polysome-associated f rritin mRNA was not accounted for 
by an increase in the overall amount of mRNA since it was 
paralleled by a decrease in the cytoplasmic post-ribosomal 
ferritin mRNA. Therefore the increase in ferritin must have 
been due, not to new messages, but to mobilization from a 
store of inactive cytoplasmic mRNA. It was first supposed 
that this cytoplasmic mRNA might be inactivated by at- 
tachment of a ferritin subunit, acting as a repressor, and 
that iron caused derepression by promoting assembly of 
subunits into ferritin 24-mers which were then able to 
incorporate iron [283,298]. Although subsequent work has 
confirmed such a proposal, the repressor protein is not a 
ferritin subunit, but a much larger molecule of M r ~ 90 
000 [299]. 
In rats, both H- and L-ferritin messengers have been 
shown to respond to iron to the same extent and in the 
same way: a shift from an inactive ribonucleoprotein frac- 
tion to polysomes [299]. Similar effects were observed in 
the bullfrog embryonic red cell without an overall increase 
in total mRNA [300-302]. Sequencing of H- and L-rat 
ferritin mRNAs showed them to have unusually long 
5'-untranslated regions (UTRs), respectively of 210 and 
168 nucleotides [299]. Within the first 75 nucleotides 
stem-loop structures are predicted by computer analysis 
[299-303]. A sequence of 28 nucleotides has been found 
to be highly conserved within putative stem-loops in the 
5'-UTRs of H- and L-ferritin mRNAs of human [304-306], 
bullfrog [301], chicken [307], rabbit [308] and the somal 
ferritin of the snail Lymnaea stagnalis [38] as well as in 
rat [299,303]. The properties and functions of this family 
of mRNA non-coding sequences have recently been re- 
viewed [309]. Fig. 12. shows selected stem loop structures 
and a consensus equence for the 28 nucleotides. Such a 
sequence has been demonstrated to be essential (and suffi- 
cient) for the translational response to iron: by deleting it 
from the 5'-UTR, by altering its sequence and by produc- 
ing iron induction of a reporter protein (chloramphenicol 
acetyltransferase (CAT) or human growth hormone) by 
construction of chimaeras in which the 5'- or 5'- and 
3'-UTR regions of a ferritin mRNA are fused to its reading 
frame [303,308,310-314]. Its position in the 5'-UTR is 
also important - if it is shifted to a position 67 or more 
nucleotides downstream from the 5'-terminus cap structure, 
iron-dependent translational regulation is lost [315]. The 
28-nucleotide sequence is now known as the iron-respon- 
sive element (IRE). Its 6-nucleotide loop sequence 
CAGUGN (where N is any nucleotide other than G), and, 
in particular, its 5' C residue are highly critical for its 
function [312,314-319]. 
Also important is a conserved cytosine within a 3- 
nucleotide bulge predicted to occur between the upper and 
lower stems [317-319]. The actual nucleotide sequence of 
the stem regions themselves is less important han the 
conservation of Watson-Crick base pairing [317,319,320]. 
In a recent study, random substitutions were made in the 
6-base loop and unpaired bulge cytosine positions, and 
sequences binding the iron regulatory protein (IRP) were 
selected from the 16 384 IRE molecules o produced [318]. 
Surprisingly loops with sequence 5'-UAGUAN bound with 
high affinity as well as the expected 5'-CAGUGN and it 
was therefore proposed that base-pairing occurs between 
positions 1 and 5 of the loop. 
Another factor, essential for iron-dependent transla- 
tional regulation, is the presence of a cytosolic protein of 
M r ~ 90 kDa, which binds specifically to the IRE with 
high affinity (Kd= 10 10 to 10 -11 M). This has been 
shown by gel retardation assays in which the radio-labelled 
RNA is incubated with cytoplasmic protein extracts [321], 
by RNA-protein cross-linking induced by UV radiation 
[299] and by competition studies with variant RNA se- 
quences [322]. This protein has been known variously as 
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the IRE-binding protein (IRE-BP), iron regulatory factor 
(IRF), ferritin repressor protein (FRP), P-90 or iron regula- 
tory protein (IRP). IRP will be used here in accordance 
with general agreement. Under normal iron levels, three 
pools of IRP are present in liver cytosol: the high affinity 
protein, the protein-mRNA complex and a low affinity 
protein [321-325]. The latter can be activated by treatment 
with thiols (2-mercaptoethanol or dithiothiothreitol) in vitro 
[321,323] or, to some extent, with the iron-chelator desfer- 
rioxamine [322]. A protein with high IRE-binding activity 
is present in cells cultured with desferrioxamine [322]. 
Conversely, the presence of iron salts or haemin in cell 
culture media causes binding activity to be diminished 50- 
to 100-fold, as does the addition of ferrous salts to the 
purified IRP [322-328]. Thus iron regulation of ferritin 
mRNA translation involves a protein able to bind iron 
reversibly; it acts as a repressor in unbound form and is 
dissociated from the messenger when it binds iron. A high 
degree of evolutionary conservation is indicated by the 
occurrence of proteins with virtually identical properties in 
rat liver extract [299], human placenta (a doublet of M,. ~ 
97 and 100 kDa) [329], rabbit liver [327] and in other 
vertebrates, insects and annelids [330]. Based on cDNA 
sequences these proteins also show a high conservation 
( > 90%) of amino acid sequence [331,332]. 
The IRP has been purified from human [333] and rabbit 
[327] liver and from human placenta [334]. Use of IRE-af- 
finity chromatography [334] ensured the isolation of a 
protein with high binding affinity for the IRE. cDNA 
clones encoding human IRP have also been isolated and 
expressed and both the cDNA and the protein have been 
sequenced [335-338]. Its gene has been localised to chro- 
mosome 9 [335]. A second protein (IRP2 or IRF B) which 
also binds IREs with high affinity has been isolated from 
humans [335] and rodents [299,339]. The human protein 
has a sequence closely similar to IRPI and was localised 
to chromosome 15. The protein (IRP2) isolated from ro- 
dent cells appears to be structurally related to IRP, al- 
though it is larger (about 105 kDa), it gives distinct peptide 
patterns and it does not react with IRPI antibodies [339]. 
Its tissue distribution is also different, giving highest IRE- 
binding activity in intestine and brain, whereas that of IRP 
is greatest in liver, intestine and kidney. The significance 
of the two IRPs is not clear. However, very recent data 
show that rat IRP2 differs from IRP1 in significant re- 
spects: unlike IRP[, IRP2 is down-regulated by iron (due 
to increased turnover) and it exhibits no aconitase activity 
and is not activated by treatment with thiols or desferriox- 
amine [340,341]. IRP1 contains 889 amino acids as does 
the protein of human placenta, for which an M r of 98 398 
is calculated [338]. Murine and rabbit IRPI have highly 
homologous equences [342]. The presence in IRP of a 
sequence CXXC, commonly found in Fe-S cluster-contain- 
ing proteins, indicated that it may contain such a cluster. 
The next major development in ideas concerning its iron- 
sensing mechanism followed from the observation that IRP 
sequences aligned well (with 30% overall identity and 
57% similarity) to the amino acid sequence of the Krebs 
cycle enzyme aconitase from porcine mitochondria 
[319,332,336-343]. Moreover, the gene for cytoplasmic 
RNA ACONITASE 
Domain 
l ~ i n  I 
Domain 2 
Fig. 13. Model of an IRE-like stem-loop and aconitase. Mitochondrial conitase is used as a model for the IRP structure. Domain 4 of the protein is 
connected todomains 1-3 by the hinge linker. Opening of the cleft between these regions probably allows loss of the [Fe-S] cluster and its replacement by 
the IRE. The arrows indicate the RNA and protein regions that are probably implicated in their interaction atthe IRE binding site. Reproduced with 
permission from [352]. 
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aconitase is, like that of IRPI, located on chromosome 9.
Aconitase is known to occur in two forms, an active 
enzyme containing a [4Fe-4S] cluster and an inactive form 
with a [3Fe-4S] cluster [344]. The inactive form can be 
activated in vitro by introduction of Fe 2÷ under reducing 
conditions, which parallel those which enable the IRP to 
bind to the IRE and act as a translational repressor. 
Comparison of the amino acid sequences of IRPs, with 
porcine, mitochondrial nd E. coli aconitases shows strik- 
ing conservation of cluster ligands and residues known to 
be involved in aconitase substrate binding and catalysis 
[342,343]. This suggested that IRP could be a functional 
aconitase. This was confirmed [345] and reciprocal RNA 
binding and aconitase activity of IRP demonstrated both in 
vitro [329] and in mouse fibroblasts [346] and a mouse 
erythroleukaemic cell line expressing human IRP [347]. 
There is now good evidence that IRP and cytosolic aconi- 
tase are one and the same: the amino acid composition and 
partial sequence data of purified beef liver cytosolic aconi- 
tase are virtually identical to those derived from the cDNA 
sequence of human IRP [348]. 
The known three-dimensional structure of bovine mito- 
chondrial aconitase has three closely integrated omains 
and a fourth domain connected by a hinge linker [349,350]. 
The [4Fe-4S] cluster is sited in a cleft between domains 4 
and domains 1-3. It is proposed there are two conforma- 
tions of the IRP, a 'closed' form that is similar to the 
known aconitase structure, and an 'open' form produced 
by movement of domain 4 and loss of iron such that it is 
enabled to recognise and bind the IRE [344,347]. It was 
first proposed that the change in activity resulted from 
alteration of the aconitase/IRP protein between [4Fe-4S] 
and [3Fe-4S] forms. However, the activity switch is now 
thought o be between the [4Fe-4S] form and the apopro- 
tein, since only the latter binds the IRE with high affinity 
comparab le  to that of  the IRP in v ivo 
[323,344,347,351,352]. The reversibility of activation/in- 
activation of aconitase/IRE binding activity of IRP(I) by 
iron salts in the presence of cysteine or iron chelator shows 
that chelatable iron does not cause degradation [324]. A 
major contact site between the IRE and IRP has recently 
been mapped with the aid of cross-linking induced by 
UV-irradiation followed by protease digestion of the com- 
plex [352]. Comparison of the isolated peptide with the 
predicted structure (based on that of mitochondrial aconi- 
tase [349,350]) placed the site of the IRE attachment deep 
within the aconitase active site cleft (Fig. 13). In this 
model the closed conformation containing the [4Fe-4S] 
cluster would be inaccessible to the RNA and cleft-open- 
ing must occur to allow IRE-binding. A similar conclusion 
has been reached by mutagenesis of three cysteines (seq. 
nos. 437, 503 and 506), which are predicted to bind the 
[4Fe-4S] cluster The three Cys ~ Ser variants howed no 
aconitase activity but, although binding was not regulated 
by cellular iron levels, they were able to bind IRE in the 
presence of [3-mercaptoethanol. Thus the IRE is able to 
bind near to Cys 437 in the absence of cluster [328-356]. 
Substitution of active site cleft arginine residues also greatly 
reduced IRE binding affinity in retardation assays 
[353,355]. 
7.4. Haemin as the ferritin inducer: an alternative model 
of regulation 
One question relating to the mechanism of ferritin 
induction that has been particularly controversial is: in 
what form does haemin exert its regulatory effect? 
Since haemin (iron protoporphyrin IX), as well as iron 
salts, is capable of inducing ferritin mRNA translation in 
tissues, cell cultures and cell-free systems (e.g., Refs. 
[129,283,297,311,326,357-361]) the question arises: does 
haemin induction require the prior degradation of the 
protoporphyrin, so as to release its iron, or does it have a 
direct effect, e.g., by binding to and modulating the struc- 
ture of the IRP? Conflicting answers have been given by 
different experimenters. Eisenstein et al. [362] concluded 
from studies in rat fibroblasts that release of iron by 
haemoxygenase is essential for its induction of ferritin 
synthesis. Swenson et al. [322] found that addition of 
haemin led to rapid breakdown of IRP complexes and 
proposed the presence of a specific haemin binding site. 
Lin et al. [360,363,364] found that haemin formed a stable 
cross-linked complex with the IRP and suggested that this 
was the principle step in the process of derepression 
leading to its dissociation from the IRE. These workers 
later concluded [357] that haem may act by triggering 
degradation of the repressor. They suggested that there 
may be two mechanisms, a reversible one involving the 
binding of an [4Fe-4S] centre by the IRP and a degradative 
and irreversible mechanism leading to decreased level of 
repressor protein. However, recent experiments with cul- 
tured mouse fibroblasts and rabbit cells grown with haemin 
or desferrioxamine showed no coupling between IRE-bind- 
ing activity measured by gel-retardation assay with radio- 
labelled IRE-containing mRNA and IRP levels obtained 
from Western blots [360]. Also no change in IRP levels 
pulse labelled with [35S]methionine could be found in cells 
treated with haemin or chelator. Tang et al. [365] con- 
cluded that iron must be released from haemin to exert its 
effect on ferritin biosynthesis n agreement with the earlier 
studies [362]. 
7.5. The untranslated regions of ferritin on RNA and the 
repression of translation: the involvement of IRE flanking 
regions ?
The stem-loop structure formed by the 28 nucleotides of 
the IRE was originally predicted by computer analysis. 
Experimental evidence supporting such secondary struc- 
ture is provided by examining the action of both protein 
(RNases) and chemical (Fe EDTA and 1,10-phenan- 
throline) nucleases on ferritin repressor-mRNA complexes 
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in in vitro systems [366,367]. 'Footprints' and 'toe-prints' 
showed that repressor protein binding was confined to the 
stem-loop, but that this binding caused increased base- 
stacking in regions flanking the stem-loop. It was proposed 
that the mRNA structure required for regulation included 
the flanking region (some 55 nucleotides in all). This 
proposal has been disputed as a result of examining the 
iron-regulated expression of human growth hormone in 
transfected mouse fibroblasts containing plasmids in which 
cDNAs, with IREs in various positions and with various 
flanking sequences, had been inserted upstream from the 
human growth hormone coding region [318,368]. The con- 
clusion from these experiments i that the most stringent 
requirement for regulation is the position (near the 5' end 
of the mRNA) of the IRE and, that provided this require- 
ment is met, the sequences flanking either end of the IRE 
are unimportant. Considerable variation in IRE sequence is
tolerated, provided its secondary structure is preserved but 
alterations, e.g., in the size of the loop, may reduce the 
affinity of the binding protein [317]. However, recent 
studies of the effects of mutation in the flanking regions 
indicated that disruption of a base-pair t iplet led to dimin- 
ished regulation, which could be regained by a second 
mutation to restore base pairing [369]. High conservation 
of the base-pair t iplet was found in 9 vertebrate sequences 
(GAG/CUC in H-ferritin and GGG/CCC in L-ferritin) 
and it was suggested that the flanking regions may en- 
hance the stem-loop-protein i teraction [369]. 
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Fig. 14. Scheme of cellular iron homeostasis in vertebrates. Cellular iron homeostasis i regulated post-transcriptionally through iron-dependent 
conformational changes of the IRP. In iron deficiency IRP has IRE-binding activity and represses the translation of ferritin H- and L-chains, and, in 
erythrocytes, also of eALAS, the major regulatory enzyme of heme synthesis. In addition binding of the IRP stabilises transferrin receptor mRNA, thus 
leading to increased protein expression. Under iron excess, IRP has low affinity for the IRE and instead has aconitase activity. This leads to derepression of
ferritin and eALAS synthesis, to destabilization of TIR mRNA, and possibly to faster aconitase turnover. This leads to a decrease in the size of the 
regulatory iron pool. IRP systems may regulate translation of other IRE-containing mRNAs (e.g., that of mitochondrial conitase). 
P.M. Harrison, P. Arosio / Biochimica et Biophysica Acta 1275 (1996) 161-203 191 
Like the 5'-UTRs, the 3'-UTRs of ferritin L-subunit 
mRNAs show extensive sequence conservation across 
species as do those of H-subunit mRNAs, although H- and 
L-mRNAs show little homology [358,373]. It has been 
suggested that these regions may also play a role in 
translational control through interactions with the IRP 
which prevent nuclease binding and stabilize the mRNA 
[358,373]. 
7.6. Co-ordinated regulation of iron metabolism 
The above discussion has focused on the translational 
control of ferritin synthesis. However, a very important 
feature of this regulation is that IREs are not confined to 
ferritin mRNA. While the latter has one IRE in its 5'-UTR, 
the 3'-UTR of transferrin receptor mRNA has flue putative 
hairpin structures, closely related to the ferritin IRE in 
sequence [313,319,336,342,371-374]. They bind the same 
IRP as binds to ferritin mRNA and at least four are able to 
bind simultaneously in 1:1 stoichiometry [329,375]. Dele- 
tion of the entire 3'-UTR leads to constitutively high 
expression of TfR mRNA [376], whereas simultaneous 
mutagenesis of all five IREs gives a non-regulated, rapidly 
degrading mRNA [316]. Iron modulation of TfR is oppo- 
site to that of ferritin: high iron levels lead to low TfR 
expression and vice versa [377-380]. Binding of IRP is 
thought to protect TfR mRNA against degradation 
[316,329]. 
Thus when iron is needed, more TfRs are synthesized 
enabling more iron to be taken up, and, when cells are 
iron-replete, more ferritin is synthesized to protect against 
its toxicity. The co-ordinated regulation of these two pro- 
cesses is summarised in Fig. 14. 
A single IRE which binds specific IRPs has recently 
also been found in the 5'-UTRs of both murine and human 
erythoid-specific 8-aminolaevulinic a id synthase (eALAS) 
mRNA [378,379] and iron regulation of eALAS synthesis 
has been demonstrated [380,381]. As with ferritin, IRP 
binding blocks initiation of translation of eALAS mRNA 
[380,381]. Large amounts of haemoglobin are produced 
during terminal stages of red cell differentiation. ALAS 
catalyses the first, and probably rate-limiting, steps of the 
haem biosynthetic pathway. Thus iron availability regu- 
lates haem biosynthesis during development of erythroid 
precursor cells in co-ordination with cellular iron uptake 
and storage [371,374]. The mRNA of porcine mitochon- 
drial aconitase also contains one IRE in its 5'-UTR, which 
binds human IRP (although not the mitochondrial enzyme), 
so aconitase synthesis itself may be regulated by iron 
[345,380]. When iron is limiting, the aconitase activity of 
IRP, and possibly the mitochrondrial enzyme, increases, 
with a consequent increase in citrate consumption. The 
reverse occurs in conditions of iron-excess, with the proba- 
ble increase in cellular citrate accumulation. The apparent 
direct coordination of citrate and iron levels may be 
physiologically important considering that citrate is one of 
the major cellular iron-binding molecules [336,380]. 
Recently implicated in the regulation of iron metabolism 
is the gas radical molecule, nitric oxide (NO). NO has 
many physiological functions including blood pressure reg- 
ulation, immunomodulation, and neurotransmission 
[382,383]. It has been shown to modulate the activity of 
iron-containing enzymes including those with [4Fe-4S] 
clusters. It has now been found to be an affector molecule 
regulating the aconitase and IRE-binding activity of IRP in 
murine macrophages and fibroblasts and in human K562 
cells and thus to provide a link between iron metabolism 
and NO pathways [384-386]. It is postulated that NO 
interacts with the [4Fe-4S] cluster of the cytoplasmic 
aconitase causing conformational rearrangement that en- 
ables it to bind the IRE. Hence NO causes repression of 
ferritin mRNA translation and stabilises the transferrin 
receptor in RNA against degradation. Alternatively, or 
additionally, it may interact directly with the iron regula- 
tory pool reducing its size [384,385,387]. In K562 cells 
iron mobilised by NO from intracellular iron compounds 
seems to be reincorporated into ferritin [388]. 
Exposure of cells to H202 also triggers a reduction in 
ferritin synthesis and an increase in synthesis of the trans- 
ferrin receptor [389]. Again H20 2 appears to lead to the 
disassembly of the [4Fe-4S] clusters of aconitase leading to 
an increase in IRE binding, but it may not do so by direct 
action on the clusters [389]. 
7.7. Non-iron mediated induction of ferritin synthesis 
Ferritin synthesis is stimulated at various levels during 
development, cellular differentiation and inflammation and 
by some hormones and cytokines, with mechanisms which 
may be partially related to decompartmentalization of cel- 
lular iron. 
Early studies showed that chemically induced inflam- 
mation in rat models increased ferritin synthesis in liver in 
two waves: the first peaked at 6 h and the second at about 
24 h [390]. More recent studies indicated that total ferritin 
mRNAs remained constant [278], but a slight decrease of 
L-chain mRNA has been observed in the liver, but not in 
the spleen at 24 and 48 h of inflammation [283]. Thus the 
up-regulation of ferritin synthesis appears to be mainly at a 
post-transcriptional level, in agreement with the observa- 
tions that a short-term incubation of hepatoma Hep G2 
cells with the inflammatory cytokine IL-1-induced ferritin 
expression by a translational mechanism, similar, but not 
identical, to that used by iron [391]. Sequences on the 5' 
untranslated region of H-ferritin mRNA appear to be re- 
sponsible for the IL-I translational up-regulation, and they 
are distinct from the IRE consensus equence [392]. Also 
other inflammatory cytokines uch as IL-6 were found to 
stimulate ferritin synthesis, probably as a secondary re- 
sponse to an increase of iron uptake [393]. Other studies 
showed that tumour necrosis factor (TNF) induces a selec- 
192 P.M. Harrison, P. Arosio / Biochimica et Biophysica Acta 1275 (1996) 161-203 
tive accumulation of H-chain mRNA in mouse adipocytes, 
human muscle cells and in the human monocytic ell line 
U937 [291,394] by an iron-independent mechanism acting 
at a transcriptional level [291]. Also IL-1 was found selec- 
tively to stimulate H-chain transcription in muscle cells, 
and the stimulation was additive to that of TNF [395]. 
Various, probably most, differentiation processes are 
associated with increases in ferritin mRNA levels, mainly 
of the H-chain. They include differentiation of the human 
promyelocytic cell line HL-60 to neutrophils and 
macrophages [391], differentiation of mouse leukaemia 
[396], and rat erythroid cells [397,398], differentiation of 
mouse TA 1 cell to adipocytes [399], differentiation of the 
non-fusing myogenic ell lines BC3HIs [400], and in vitro 
differentiation of monocytes to macrophages [292]. The 
more tumorigenic human colon carcinoma cell lines ex- 
press higher amounts of H-chain mRNA due to a specific 
increase in transcriptional rate, possibility stimulated by 
c-myc proteins [401]. In myogenic ell lines the increase 
was specific to H-chain mRNA and induced by cAMP 
[4OO]. 
Rat thyroid cell respond to the thyroid-stimulating hor- 
mone TSH with an increase of H-chain mRNA [402] 
probably mediated by cAMP. The response is mediated by 
a product which acts in trans on the ferritin promoter 
[402]. Insulin stimulated steady-state l vels of H- and 
L-chain mRNAs in cultured rat glioma cells at a transcrip- 
tional level [403]. Incubation of rat pancreatic insulin cells 
with glucose induced a dramatic increase of H-chain and a 
decrease of L-chain mRNAs levels, under conditions that 
change the level of insulin mRNA and cellular capacity to 
release insulin [404]. Ferritin synthesis in the liver of 
Xenopus leavis is stimulated by estrogens [405]. Some cell 
types appear to respond to alterations of the redox status 
with an up-regulation of ferritin synthesis at a post-tran- 
scriptional evel: this has been observed in oligodendro- 
cytes cultured in hypoxic conditions [406] and in 
macrophages xposed to sulphydryl-reactive agents under 
hypoxic conditions [407]. Arsenite was reported to up-reg- 
ulate ferritin H-chain mRNA in HeLa cells, possibly due to 
an increased level of oxygen radicals [408]. Treatments of 
rats with phorone, a glutatione depleting drug, was found 
to greatly stimulate ferritin expression in the liver, and the 
effect was attributed to iron decompartimentalization 
caused by the oxidative stress [409]. 
Hydroxyurea-resistant cells were found to have an up- 
regulated synthesis of M I and M2 subunits of ribonu- 
cleotide reductase and of both ferritin subunits [410]. These 
cells had higher levels of ferritin mRNAs partially caused 
by gene amplification [410]. 
Other mechanisms that regulate ferritin expression seem 
to involve the modulation of transcript stability. Mattia et 
al. [411] showed that heme induces an increased expres- 
sion of ferritin in human erytholeukemic K562 cells by an 
increase of mRNA half-life. This was suppressed by the 
inhibition of protein synthesis, suggesting that it was pro- 
tein-mediated. Other studies showed that the different 
steady-state l vels of H- and L-chain mRNAs in human 
hepatoma cell lines at different stages of differentiation 
were caused mainly by differences in the stability of the 
transcripts and not by transcription rates [296]. 
8. The ferritin genes 
Multiple copies of both H- and L-ferritin genes have 
been found in humans and other animals, most of them 
being intron-less pseudogenes. Man has about 16 copies of 
the H-gene [304] and 5 copies of the L-gene [305]. The rat 
genome contains about 20 copies of L-gene [306] and 4 
copies of the H-gene [303], mouse has 3 H-genes and 
10-14 L-genes [412]. In contrast chicken contains a single 
copy of the H-gene [307]. In each case only a single active 
gene has been identified. Some curiosity was stimulated by 
the location of H-genes on human chromosome 6, which is 
also the locus of genetic haemochromatosis. Two of these 
have been identified, but they are inactive pseudogenes 
[413]. The functional human H- and L-genes have been 
located on chromosome 11q23 and 19 respectively 
[414,415], and the mouse H-gene on the B-region of 
chromosome 19 [416]. The structures of genomic H-genes 
of human [304,417] mouse [418,419], rat [303] and chicken 
H-chain [307] and of the L-genes of human [305] and rat 
[306] have been reported. They all contain 3 introns of 
different lengths which splice the sequence in constant 
positions [420]. The 5' flanking regions of H- and L-chain 
genes bear no similarities, while a high degree of conserva- 
tion has been found among the chains of different species. 
Functional analyses of a relatively short portion of the 
5' flanking regions (about 500 bp) has been reported for 
the human H-gene. The genomic sequences were fused to 
the CAT reporter gene and used in transient expression 
experiments and DNA-protein interactions assays. Three 
regulatory regions were identified. One, named A region, 
has been located between t - 132 and - 109 upstream of 
the transcription i itiation site. It is recognised by the RNA 
polymerase II transcription factor SP1 [421], and is respon- 
sible for about 50% of the activation of gene expression in 
various cell lines. A second regulatory sequence (B box) 
located from -62  to -42  nt is recognised by an unchar- 
acterized cis-acting element, which enhances transcription 
and is more abundant in cells treated with the antibiotic 
geneticin [422]. A third regulatory sequence is between t 
-272  and -291,  and, being G-rich, has been named 
G-fer [423]. It binds a nuclear factor present in different 
cell types which has properties very similar to the in- 
hibitory factor-1 (IF-l). This is an ubiquitous factor that 
interacts with similar G-rich elements of the mouse type-I 
collagen genes. Alteration of the G-fer site increased pro- 
moter activity by about 8-fold [423]. A 400 bp H-chain 
promoter was sufficient o confer TSH-dependent regula- 
tion to an heterologous CAT gene [402]. The cloning of a 
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longer sequence of the mouse ferritin H-chain gene al- 
lowed identification of regulatory regions 4-5 kilobases 
upstream of the transcription start site. One region of 37 
bp, named FER-1, at 4.1 Kb 5' of the transcription i itia- 
tion site, acts as an enhancer and as a target of the 
adenovirus oncogene EIA-mediated repression [424]. The 
second region identified, named FER-2, which is of 40 bp 
is located further upstream (4.8 kb form transcription start 
site) and contains a perfect match to the consensus binding 
motif to the erythroid transcription factor NF-k2, and a 
second sequence that may bind a different member of the 
NK-kB/Rel family [425]. FER-2 constitutes the major 
regulatory TNF-responsive lement of the H-gene, and 
may be important in the induction of ferritin synthesis 
caused by oxidative stress, mediated by NF-kB transcrip- 
tion factors. 
A study on ferritin in fetal brain identified an unusually 
long H-chain transcript arising from an alternative 
polyadenylation site. It contained an additional 279 nt at 
the 3' untranslated region [426]. The transcript was found 
in various tissues, with the highest relative concentration i  
brain, kidney and lung [427]. 
9. Other biological functions associated with ferritins 
There are indications that ferritins may have other 
functions in addition to the well assessed role in storing 
intracellular iron in a non-toxic and bioavailable form. 
Ferritins are found in unicellular organisms where the 
needs for iron storage are not obvious [30]; also they are 
present in high concentrations in some cells, which are 
iron-poor such as insulin-secreting cells [404] and the 
ferritins found in human body fluids clearly do not store 
iron [428]. The additional functions attributed to ferritins 
found inside and outside the cell are summarised below. 
9.1. Ferritin and oxidative damage 
It has often been suggested that ferritins detoxify intra- 
cellular iron [428], but how they perform this protective 
role remained unclear. Iron toxicity is mainly related to its 
capacity to promote the formation of reactive oxygen 
species (ROS) which are the major effectors of oxidative 
damage [429]. This is associated with a 'free' iron or 
non-heme iron pool consisting of low molecular iron com- 
plexes, the concentration of which is extremely low and 
probably regulated by ferritins. In most cells, ferritin is the 
most abundant and most concentrated form of iron. Stored 
in ferritin this iron is relatively inert as a promoter of ROS 
formation, but it becomes active when released by reduc- 
ing agents [430]. The physiological reductant (and toxi- 
cant) oxygen superoxide produced by xanthine-xanthine 
oxidase [431] or by stimulated polymorphonuclear leuko- 
cytes [432] can release a minor proportion of ferritin iron 
[433], which is sufficient to promote lipid peroxidation 
[434]. Also the toxicant, redox cycling, xenobiotics, includ- 
ing Paraquat, adriamycin and alloxan, mobilize ferritin 
iron. They can produce free radicals with reduction poten- 
tials enabling them to stimulate ferritin iron release and 
lipid peroxidation [430,435-437]. Nitric oxide binds to 
ferritin [200] and it was reported to mobilise ferritin iron 
and thus to promote lipid peroxidation [258], but its role as 
a pro-oxidant has been questioned [438,259]. Adryamicin- 
induced iron release was greater in ferritins with higher 
L-chain content [439]. These in vitro results lead to the 
suggestion that an unregulated release of iron from ferritin 
caused by ischemia, inflammation or xenobiotics may be 
sufficient to catalyse oxidative damage [430]. However, 
direct evidence that ferritin has a pro-oxidant activity in 
vivo is still missing. 
Iron-induced ROS formation is linked to the presence of 
ferrous iron [429] and enzymatic systems that remove 
ferrous ions are expected to reduce iron toxicity. This has 
been demonstrated for ceruloplasmin [440] and for ferritin 
H-homopolymers [441 ] both having ferroxidase activity. In 
contrast, ferritin L-homopolymers did not reduce iron-in- 
duced lipid peroxidation. This suggested that ferritin may 
have an anti-oxidant function, that is related to its subunit 
composition. Additional evidence that ferritin has a protec- 
tive role in oxidative damage came from studies on cellu- 
lar systems. Balla and collaborators [442] showed that the 
cytotoxicity of oxidative agents on endothelial cells was 
strongly reduced by pre-incubating the cells with heme 
iron. The reduction of the activity was parallel to the 
increase of endogenous ferritin expression. Also exoge- 
nous ferritins which were taken up by the cells showed 
protective ffects, provided that they had ferroxidase activ- 
ity [442]. The increase in ferritin synthesis was apparently 
mediated by heme oxygenase, an enzyme induced by 
oxidative stress which liberates iron from heme [443,444]. 
The released iron stimulates ferritin synthesis through the 
IRE-IRP machinery. It was proposed that the newly syn- 
thesised ferritin reduced the amount of iron available for 
ROS production and cellular damage. This proposal is 
consistent with the observations that the toxicity of oxida- 
tive agents [445] on various tumour cell lines decreased 
with the increase of intracellular ferritin content. Similar 
observation was made with TNF, the cytotoxic effect of 
which may be linked to oxidative damage [446]. A specific 
induction of H-chain synthesis induced by TNF [291] or by 
transfection [447] was found to reduce the expression of 
L-chain, probably due to an activation of IRP caused by 
iron deprivation. This provides indirect evidence that H- 
chain ferroxidase activity directly regulates the size of an 
'intracellular transit iron pool', which may participate in 
oxidative damage. 
Thus, recent data support he hypothesis that ferritin has 
iron-detoxifying functions. However, under particular 
patho-physiological conditions, iron release from ferritin 
may be unregulated and ferritins may act as pro-oxidant 
agents. 
194 P.M. Harrison, P. Arosio / Biochimica et Biophysica Acta 1275 (1996) 161 203 
9.2. Regulators of protein synthesis? 
Studies directed to the analysis of non-ribosome-bound 
RNP structures in duck erythroblasts identified a 
prosome-like particle with a strongly inhibitory effect on 
in vitro translation of globin and non-globin mRNAs [448]. 
Later, the particle was identified as a ferritin molecule, 
based on its amino acid sequence and chemico-physical 
and immunological properties [449]. More recently, the 
characterisation f the U-particles which accumulate in 
mouse L-cells following infection with mengovirus re- 
vealed them to be mouse ferritin molecules [450]. The 
U-particles were found to inhibit mRNA translation in 
vitro [450]. Additional evidence that ferritins may have a 
role in the regulation of protein synthesis came from a 
report by Wu and Noguci [451 ]. They co-transfected HeLa 
cells with cDNAs of H- and L-ferritin chains together with 
globin promoters fused to reporter genes. The expression 
of the reporter genes was up-regulated by both H- and 
L-ferritin chains, (with L having a stronger effect), sug- 
gesting that ferritin may have a direct role in globin gene 
expression. Presently it is unclear whether these putative 
effects of ferritin on protein synthesis are related to iron. 
9.3. Extracellular ferritins 
Some insects and molluscs secrete a large amount of 
iron-containing ferritin which may function as an iron 
transport molecule. These ferritins have a leader sequence 
for membrane targeting and processing [33,40]. It remains 
to be studied where and how they incorporate iron in the 
secretary pathway. Largely obscure are the origin and 
mechanism of production of the extracellular ferritins found 
in mammals for which, so far, no transcripts with appropri- 
ate signal sequences have been identified. Part of the 
circulating tissue ferritin probably arises from tissue dam- 
age, but the presence of specifically glycosylated subunits 
and its tight regulation in response to iron and to various 
inflammatory conditions indicate that most of it is actively 
secreted. The extracellular ferritins found in serum and 
body fluids account for a minor proportion of total ferritin. 
They are typically iron-poor and their structures vary from 
having no detectable H-chain in serum [452] to a high 
proportion of H-chain in milk [453]. There is no direct 
evidence that the ferritins in body fluids have functional 
roles, and the indication that the secreted ferritins are 
functionally active is based on studies with recombinant 
and extracted intracellular ferritins and on the identifica- 
tion of specific receptors on various cellular membranes. 
Such receptors have been described in liver cells 
[267,271,272], on human lymphocytes and erythroblasts 
[454,455], on adipocytes [456] and on various cell lines 
[457-459]. It is presently unclear how many ferritin recep- 
tor types exist, but a major difference between the ones 
found on liver cells and on the other cell types is evident. 
The hepatic receptors have a broad specificity with respect 
to H and L composition and even across species [460], 
while those on lymphocytes and cells lines are specific for 
the H-chain [454-457,460]. They seem to have distinct 
roles in the transfer of iron among different cells and in the 
regulation of cellular proliferation and function. 
9.4. Ferritin and the regulation of cellular proliferation 
Broxmeyer and collaborators in 1981 proposed that 
ferritins have a regulatory role in the production of granu- 
locytes and macrophages [461]. The hypothesis that a 
sub-population f ferritins has suppressive activity on bone 
marrow myeloid progenitor cells was later confirmed by 
the use of recombinant homopolymers of H- and L-chains 
in vitro and in vivo [462,463]. This activity was found to 
be associated not only with the H-chain, but also with its 
ferroxidase activity. It could be reversed either by the 
supplementation f heine iron to the progenitors cells, or 
by an excess of an H-chain variant with an inactivated 
ferroxidase centre [462]. A current hypothesis is that the 
suppressive activity is exerted via the binding to the 
specific H-chain receptors and by the interference of the 
ferroxidase activity with cellular iron uptake. Similar sup- 
pressive activity has been found on the proliferation of 
stimulated lymphocytes [454] and K562 cells [455]. Cells 
from patients with haematological disorders are less sensi- 
tive to the myelosuppressive activity of H-ferritin, thus 
favouring the progression of the disease [464]. More re- 
cently it has been shown that a sub-population of mononu- 
clear phagocyte progenitor cells is sensitive to ferritin 
suppression [465]. This sub-population consists of pre-lin- 
eage commitment progenitors, which need bacterial ipo- 
polysaccharide to respond to the specific growth factor 
M-CSF. This suppressive activity appears to be mediated 
by a cytokine produced by adherent macrophages respond- 
ing to H-ferritin [466]. Also in this case the H-ferritin with 
an inactivated ferroxidase centre was not effective in sup- 
pressing cellular proliferation. The mechanism of this ac- 
tion is far from clear. 
Other studies showed that the proliferation of cells in 
serum-free medium is stimulated, to some extent, by fer- 
ritin. This was found in neuroblastoma cell lines, the 
growth of which was stimulated 1.4-fold by the addition of 
ferritin [467]. Human erythroleukemia K562 cells [468] 
and the human lung cancer T3M-30 cells [469] grown in 
protein-free media were found to release into the medium 
a ferritin which stimulated growth of various cells, includ- 
ing leukaemia HL60 and melanoma SK-28. Whether the 
stimulus was due to iron associated with the molecule was 
not studied. Recently it has also been shown that natural 
ferritins rich in H- and L-chains suppress antibody produc- 
tion in B-cells [470]. In Epstein-Barr-virus transformed 
human B-lymphoblastoid cell lines ferritin inhibited the 
expression of mRNA. This is additional evidence of the 
suggested immunosuppressive activity of ferritin. 
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9.5. Genetic hyperferritinaemia 
Of particular interest is the recent description of a 
genetic, autosomal and dominant form of hyperferriti- 
naemia. Three families have been reported in Italy and 
France [471-473]. All the affected subjects show high 
serum ferritin levels (about 10 times normal), and congeni- 
tal cataract. Those who were treated by phlebotomy readily 
became iron-deficient but their serum ferritin levels re- 
mained unchanged. The identification of a point mutation 
in the IRE loop sequence of L-chain mRNA explained 
both the dominant transmission and the lack of response of 
the hyperferritinaemia to iron deprivation [472,473]. The 
mutations identified in the Italian and French families were 
different, but both led to reduced IRE affinity for IRP. 
Analyses of an immortalised cell line obtained from one 
patient showed a normal level of L-chain mRNA and 
abnormally high levels of L-type ferritin which are not 
modulated by iron [473]. This is consistent with L-chain 
expression which is not under the control of the iron-IRP 
machinery, and is constitutively expressed. Data from the 
few tissues analysed indicate that the intracellular L-ferri- 
tin levels, like those of serum ferritin, are several-fold 
higher in the patients than in normal subjects. This is 
strong evidence that the same (defective) gene encodes for 
both intracellular and secreted serum ferritin. Probably, the 
most surprising finding was that despite the abnormal high 
levels of L-ferritin in all tissues, the subjects show no 
evident abnormalities except for neonatal cataract, the 
severity of which varies in the different families. Thus, 
crystalline lens may be the only tissue which is sensitive to 
L-chain overexpression, for unknown reasons. The ery- 
thron and other tissues strongly dependent on iron are 
apparently unaffected, and body iron metabolism and ab- 
sorption are normal. The apparent passive role of L-chains 
is probably due to their lack of ferroxidase activity, imply- 
ing that this activity is necessary for the full functionality 
of ferritin. In fact cell lines overexpressing H-ferritin show 
an iron-deficient phenotype [447], consistent with an ex- 
panded iron storage compartment, whereas cells lines over- 
expressing L-chain do not [473]. 
10. Conclusions and perspectives 
The ubiquitous distribution of ferritin in all iron-con- 
taining organisms implies that this protein is essential for 
the handling of cellular iron. It is clear that the structural 
architecture of this molecule is remarkably well conserved 
and so is its capacity to incorporate iron. Its unique 
structure is designed to keep polynuclear i on in a soluble 
and available form, which has a limited crystallinity. Most, 
and probably all, ferritins (except perhaps serum ferritin) 
have ferroxidase activity, i.e., catalyse the conversion of 
the toxic Fe(II) into the less dangerous Fe(III). This is 
important not only for facilitating iron sequestration, but 
probably also in regulating intracellular i on speciation and 
chemical reactivity. The essentiality of ferritin, even for 
cells with no obvious need for iron storage may be due to 
these dual roles: to regulate iron toxicity and to avoid 
formation of polynuclear forms from which iron bioavail- 
ability is not easily controlled. Recent findings of 
goethite-like structures in some pathological iron-over- 
loaded tissues indicate that conditions may exist in which 
the cell's ability to store iron in ferritin is either bypassed 
or saturated. The mechanism of ferritin iron incorporation, 
although not fully understood, appears to follow conserved 
pathways from bacteria to mammals: iron is taken up 
through pores in the protein shell, is oxidised at specific 
sites (at least initially), and laid down as inorganic material 
in a preformed cavity. Ferritins from different origins have 
sequence differences, some of which may reflect a re- 
sponse to a cellular need. It is difficult presently to assess 
the biological significance of these differences, due to 
limitations in the tests for ferritin functionality, which are 
mainly based on largely non-physiological in vitro sys- 
tems. Although unravelling iron storage mechanisms based 
on in vitro experimentation is exciting and important, still 
more challenging, and ultimately of even greater impor- 
tance, is how and from what pool, ferritin acquires its iron 
in vivo. Little information is currently available ither on 
the types of iron accessible to ferritin in vivo or on the 
effects of cellular components on ferritin iron uptake and 
release. Novel and more physiological systems are now 
needed to analyse the various biological roles of the 
ferritins, including one of the least well understood aspects 
of iron metabolism: how iron moves from one molecule to 
another. The discovery of the dual activity of IRP and the 
recognition that routes of iron utilisation (e.g., heme syn- 
thesis), iron absorption and storage are under tight co- 
ordination have clarified relationships between cellular 
iron uptake, utilisation and sequestration. Citrate is also 
regulated by IRP, and this has led to the speculation that 
this potential iron chelator may have a role in intracellular 
iron exchange, but its effects on ferritin activity have not 
been studied in detail. IRP is the sensor of cellular iron 
status in vertebrates, and ferritin is probably the molecule 
which actively regulates intracellular iron levels. Such 
regulation is likely to be both dynamic and complex, 
involving modulation in rates of iron sequestration and 
release, alteration in the redox status of iron and interac- 
tion with many as yet unidentified cellular components. 
The understanding of the biological functions of the iron 
storage compartment is a major challenge which is rele- 
vant not only to normal physiology but to many diseases 
associated with perturbations of iron metabolism. 
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